
Cumulative Index

Volume 42, Numbers 1-4, 1999

- Abdominal delivery, elective, protective effect against childbirth-related perineal trauma, 820
- Abdominal hysterectomy, 939
and vaginal hysterectomy, comparison of, 939
- Abdominal pregnancy, 2, 31
mortality rate in, 31
- Abdominal wall, endometriosis of, 699
in males, 699
- Abortion
early induced
complications of, management of, 290
evaluation of patient for, 290
failed, management of, 290
frequency of, 290
hemorrhage with, management of, 290
incomplete, management of, 290
medical regimens for, 290
method for, selection of, 290
office management of, 290
patient preparation for, 290
pelvic infection after, management of, 290
surgical methods for, 290
uterine perforation in, management of, 290
failed, management of, 290
first-trimester surgical, 290
operative techniques for, 290
pain management for, 290
postoperative care for, 290
postoperative tissue examination, 290
setting for, 290
supplies for, 290
incomplete, management of, 290
induced
frequency of, 290
medical regimens for, 290
symptoms and side effects, management of, 290
methotrexate-misoprostol method, 290
mifepristone-misoprostol method, 290
mifepristone-prostaglandin method, 290
vacuum aspiration for, 290
spontaneous, 9. *See also* Termination of pregnancy and cervical pregnancy, 9
- Accessory spleen, 664
- Acebutolol, for mild gestational hypertension/preeclampsia, 455
- Acne, androgen replacement therapy and, 883
- Activated protein C resistance, and preeclampsia risk, 422
- Acupuncture, for pain relief, 664
- Acute fatty liver of pregnancy, 551
clinical presentation of, 551
comorbidity with, 551
differential diagnosis of, 381, 532
epidemiology of, 551
laboratory findings in, 532, 551
outcomes with, 551
pathophysiology of, 551
thrombocytopenia with, 327
treatment of, 551
- Acyclovir
for herpes simplex virus, 149
for neonatal herpes, 81, 134
in pregnancy
pharmacokinetics of, 134
safety of, 134
- Acyclovir suppression
animal studies on, 134
and asymptomatic shedding, 134
trials of, in pregnancy, 134
- Addiction, 664
- Adenocarcinoma, of endometriotic origin, 699
- Adenomyosis, versus endometriosis, 664
- Adhesions
intrauterine, hysteroscopic treatment of, 276
and pelvic pain, 633
surgical management of, 633, 664
- Adnexal mass. *See also* Ovarian cancer; Ovarian tumor
diagnosis of, color flow Doppler ultrasound in, 902
- β -Adrenergic agents, tocolytic therapy using, 802
in combination regimens, 802
- β -Adrenergic receptor antagonists
for acute severe hypertension in pregnancy, 519
for mild gestational hypertension/preeclampsia, 455
- Advanced Breast Biopsy Instrumentation, 234
- AFL. *See* Amniotic fluid index
- AFS (American Fertility Society). *See* American Society for Reproductive Medicine
- Agglutination test, for toxoplasmosis diagnosis, 81, 149
- Alanine aminotransferase
in HELLP syndrome, 381, 532
and hepatitis C, 121
- Alcohol use, maternal, and pregnancy outcome, 725
- Alloimmune thrombocytopenia, 335
antigens causing, 335
clinical features of, 335
clinical history with, 335
complications of
fetal, 335
neonatal, 335, 368

Page numbers indicate first page of relevant article.

Cumulative Index

Volume 42, Numbers 1-4, 1999

- Abdominal delivery, elective, protective effect against childbirth-related perineal trauma, 820
- Abdominal hysterectomy, 939
and vaginal hysterectomy, comparison of, 939
- Abdominal pregnancy, 2, 31
mortality rate in, 31
- Abdominal wall, endometriosis of, 699
in males, 699
- Abortion
early induced
complications of, management of, 290
evaluation of patient for, 290
failed, management of, 290
frequency of, 290
hemorrhage with, management of, 290
incomplete, management of, 290
medical regimens for, 290
method for, selection of, 290
office management of, 290
patient preparation for, 290
pelvic infection after, management of, 290
surgical methods for, 290
uterine perforation in, management of, 290
failed, management of, 290
first-trimester surgical, 290
operative techniques for, 290
pain management for, 290
postoperative care for, 290
postoperative tissue examination, 290
setting for, 290
supplies for, 290
incomplete, management of, 290
induced
frequency of, 290
medical regimens for, 290
symptoms and side effects, management of, 290
methotrexate-misoprostol method, 290
mifepristone-misoprostol method, 290
mifepristone-prostaglandin method, 290
vacuum aspiration for, 290
spontaneous, 9. *See also* Termination of pregnancy and cervical pregnancy, 9
- Accessory spleen, 664
- Acebutolol, for mild gestational hypertension/preeclampsia, 455
- Acne, androgen replacement therapy and, 883
- Activated protein C resistance, and preeclampsia risk, 422
- Acupuncture, for pain relief, 664
- Acute fatty liver of pregnancy, 551
clinical presentation of, 551
comorbidity with, 551
differential diagnosis of, 381, 532
epidemiology of, 551
laboratory findings in, 532, 551
outcomes with, 551
pathophysiology of, 551
thrombocytopenia with, 327
treatment of, 551
- Acyclovir
for herpes simplex virus, 149
for neonatal herpes, 81, 134
in pregnancy
pharmacokinetics of, 134
safety of, 134
- Acyclovir suppression
animal studies on, 134
and asymptomatic shedding, 134
trials of, in pregnancy, 134
- Addiction, 664
- Adenocarcinoma, of endometriotic origin, 699
- Adenomyosis, versus endometriosis, 664
- Adhesions
intrauterine, hysteroscopic treatment of, 276
and pelvic pain, 633
surgical management of, 633, 664
- Adnexal mass. *See also* Ovarian cancer; Ovarian tumor
diagnosis of, color flow Doppler ultrasound in, 902
- β -Adrenergic agents, tocolytic therapy using, 802
in combination regimens, 802
- β -Adrenergic receptor antagonists
for acute severe hypertension in pregnancy, 519
for mild gestational hypertension/preeclampsia, 455
- Advanced Breast Biopsy Instrumentation, 234
- AFL. *See* Amniotic fluid index
- AFS (American Fertility Society). *See* American Society for Reproductive Medicine
- Agglutination test, for toxoplasmosis diagnosis, 81, 149
- Alanine aminotransferase
in HELLP syndrome, 381, 532
and hepatitis C, 121
- Alcohol use, maternal, and pregnancy outcome, 725
- Alloimmune thrombocytopenia, 335
antigens causing, 335
clinical features of, 335
clinical history with, 335
complications of
fetal, 335
neonatal, 335, 368

Page numbers indicate first page of relevant article.

- cordocentesis in
 - determination of need for, 335
 - indications for, 335
- diagnosis of, 335
- in female relatives of patient, 335
- fetal
 - natural history of, 335
 - treatment of, 335
- genetics of, 335
- laboratory features of, 335
- neonatal, 335
 - incidence of, 368
 - IVIG for, 368
 - pathophysiology of, 327, 368
 - treatment of, 368
- pathophysiology of, 335
- screening for, 335
- subsequent pregnancy after, 335
 - diagnostic testing in, 335
- treatment of, 335
- Alpha-fetoprotein
 - elevation of, antepartum surveillance for, 766
 - maternal serum, for parvovirus diagnosis, 107
- Alternative medicine, 306
 - for endometriosis-related pain, 664
- Ambulatory gynecology, 183
- American Academy of Family Physicians, on neonatal circumcision, 849
- American Academy of Pediatrics, on neonatal circumcision, 849
- American College of Obstetricians and Gynecologists
 - guidelines for vaginal birth after cesarean section, 836
 - recommendations, for prenatal care, 725
 - recommendations for antepartum surveillance in post-term pregnancy, 766
- American College of Radiology, classification of mammography results, 234
- American Fertility Society. *See* American Society for Reproductive Medicine
- American Society for Reproductive Medicine, classification (staging) of endometriosis, 611, 645, 664, 699
 - Revised (R-AFS), 611
- Amniocentesis
 - in HELLP syndrome, 381
 - for parvovirus diagnosis, 107
- Amnioinfusion, in vaginal birth after cesarean section, 836
- Amniotic fluid
 - abnormalities of, sonographic findings, 71
 - meconium-stained, risks associated with, 766
- Amniotic fluid index, 71
- Amniotomy, for induction of labor, 757
- Ampullary pregnancy, 9
- Anal canal, endometriosis in, 699
- Analgesia
 - for endometriosis-related pain, 620
 - epidural. *See* Epidural analgesia
 - for pelvic pain, 620, 664
 - postoperative, management of, 664
 - for trial of labor after cesarean delivery, 836
- Anal sphincter, childbirth-related damage to, 820
- Anatomic abnormalities, with endometriosis, 586
- Androgen(s)
 - circulating levels of, postmenopausal changes in, 883
 - deficiency, postmenopausal, 883
 - and lipoprotein metabolism, 883
- Androgen replacement therapy
 - administration of, 883
 - adverse effects and side effects of, 883
 - and bone density, in postmenopausal women, 883
 - and estrogen replacement, combined, postmenopausal benefits of, 883
 - and libido, 883
 - and mood, 883
 - psychological benefits of, 883
 - and vasomotor symptom relief, 883
- Androstenedione, circulating levels of, postmenopausal changes in, 883
- Anemia, with parvovirus infection, 107
 - aplastic crisis in, 107
 - in immunocompromised patients, 107
- Anesthesia
 - in Bernard-Soulier syndrome, 390
 - in congenital platelet dysfunction disorders, 390
 - postoperative, management of, 664
- Angiogenesis, in ovarian cancer, 902
- Angiogenic growth factors, in endometriotic lesions, 566
- Anovulation, with endometriosis, 586
- Antibiotics, lupus induced by, 381
- Anticardiolipin antibodies
 - in antiphospholipid syndrome, 368
 - and endometriosis, 979
 - laboratory detection of, 979
 - and preeclampsia risk, 422
- Anticholinergic therapy
 - adverse effects and side effects of, 249
 - for urinary incontinence, 249
- Antiepileptic agents, lupus induced by, 381
- Antifungal therapy
 - for vulvar vestibulitis, 945
 - for vulvovaginal candidiasis, 184
- Antigen capture assay, in phase III antiplatelet antibody assay, 317
- Antigenemia tests, in perinatal infections, 59
- Antihypertensives
 - for acute severe hypertension in pregnancy, 519
 - oral administration of, 519
 - parenteral administration of, 519
 - in HELLP syndrome, 532
 - lupus induced by, 381
 - for mild gestational hypertension, 455
 - for preeclampsia, 455, 519
 - in expectant management, 470
 - intrapartum, 455
 - and preeclampsia prevention, 436
 - and seizure prophylaxis, in preeclampsia/eclampsia, 507
- Antinuclear antibodies, and endometriosis, 979
- Antiphospholipid antibody syndrome
 - clinical features of, 368, 979
 - diagnosis of, 979
 - and HELLP syndrome, 532
 - heparin and low-dose aspirin therapy in, 436, 979
 - IVIG for, 368, 979
 - laboratory features of, 368, 979
 - and preeclampsia risk, 422
 - and pregnancy, 551
 - pregnancy-associated

- complications of, 368
- outcomes with, 368
- treatment of, 368
- recurrent pregnancy loss with, 368, 979
 - aspirin, heparin, and prednisone therapy for, 979
 - therapy for, 979
- thrombocytopenia with, 327
- Antiplatelet agents, in prevention of preeclampsia, 436
- Antiplatelet antibodies
 - in alloimmune thrombocytopenia, 335, 368
 - testing for, 335
 - assays for, 317
 - phase I, 317
 - phase II, 317
 - phase III, 317
 - in autoimmune thrombocytopenia, 317
 - in idiopathic thrombocytopenic purpura, in pregnancy, 327
 - in thrombocytopenia, testing for, 349
- Antiprogestins, for endometriosis, 620
- Antisperm antibodies. *See* Sperm antibodies
- Antiviral therapy, for herpes, 134
- Aplastic crisis
 - causes of, 107
 - diseases associated with, 107
 - with parvovirus infection, 107
- Aromatase production, in endometriotic lesions, 566
- ART. *See* Assisted reproductive technologies
- Arthralgias, and parvovirus infection, 107
- Arthritis, and parvovirus infection, 107
- Ascites, in preeclampsia, 455
- Ascorbic acid, serum, in preeclampsia, 436
- Aspartate aminotransferase
 - in HELLP syndrome, 381, 532
 - testing for, specificity and sensitivity of, 163
- Aspirin
 - for antiphospholipid syndrome, 368
 - antiplatelet effects, 349, 390
 - for immune-associated pregnancy failure, 979
 - low-dose
 - in antiphospholipid syndrome, 436
 - in prevention of preeclampsia, 436
- Assisted reproductive technologies, 2. *See also* Infertility
 - diagnosis of ectopic pregnancy and, 9
 - for endometriosis-associated infertility, 687
 - cost analysis for, 687
 - indications for, 687
 - outcomes, in research, 687
 - pregnancy rates with, 687
 - research, outcomes in, 687
 - severity of disease and, 687
 - types of, 687
- AST. *See* Aspartate aminotransferase
- Asymptomatic shedding, of herpes, 134, 149
- acyclovir suppression and, 134
- Atenolol, for mild gestational hypertension/preeclampsia, 455
- Atosiban, tocolytic therapy using, 802
- Autoantibodies
 - and endometriosis, 979
 - and infertility, 979
 - prevalence of, in in vitro fertilization patients, 979
 - and recurrent pregnancy loss, 979
 - and in vitro fertilization failure, 979
- Autoimmune disease
 - platelet dysfunction in, 349, 360
 - and thrombotic thrombocytopenic purpura, association of, 360
- Autoimmune thrombocytopenic purpura
 - in children and adolescents, 317
 - clinical presentation of, 317
 - course of, 317
 - diagnosis of, 317
 - differential diagnosis of, 317
 - epidemiology of, 317
 - laboratory findings in, 317
 - management of, 317
 - obstetric considerations in, 317
 - pathophysiology of, 317
 - in pregnancy
 - fetal complications of, 317
 - management of, 317
 - neonatal complications of, 317
 - pregnancy-associated, 368
 - IVIG therapy for, 368
- Autoimmunity, with endometriosis, 586
- AutoPap, 206
 - in cervical cancer screening, evaluation of, 922
- Autoregulation, cerebral, loss of, and hypertensive encephalopathy, 519
- Ayre spatula, in cervical cancer screening, evaluation of, 922
- Azathioprine, for autoimmune thrombocytopenic purpura, 317
- Azithromycin, for syphilis, 97
- Bacterial infection, and vulvar vestibulitis, 945
- Bacterial vaginosis, 184
 - clinical associations with, 184
 - diagnosis of, 184
 - microbiology of, 184
 - pathogenesis of, 184
 - and preterm birth, 184
 - recurrence of, 184
 - treatment of, 184
 - nonresponders, management of, 184
 - in pregnancy, 184
- Bagel sign, of ectopic pregnancy, 39
- Balanoposthitis, 849
- Batley's operation, 939
- Bayes' Theorem, 163
- B-cells
 - fetal, 59
 - nonspecific polyclonal, activation, with endometriosis, 586
- Beckwith-Wiedemann syndrome
 - antepartum surveillance for, 766
 - follow-up with, 766
 - pathophysiology of, 766
- Bed rest, in prevention of preeclampsia, 436
- Behavioral therapy, for vulvar vestibulitis, 945
- Benzathine penicillin G
 - allergy to, 97
 - for syphilis, 97, 149
- Bernard-Soulier syndrome, 349
- anesthesia considerations with, 390
- family/personal history in, 390
- hemorrhagic complications of, 390
- laboratory diagnosis of, 390

- pathophysiology of, 390
- platelet aggregation patterns in, 349
- pregnancy management in, 390
 - antepartum measures for, 390
 - intrapartum measures for, 390
 - postpartum measures for, 390
- prenatal diagnosis of, 390
- Beta-mimetics
 - cardiovascular effects of, 802
 - metabolic effects of, 802
 - respiratory effects of, 802
 - tocolytic therapy using, 802
 - administration of, 802
 - adverse effects and side effects of, 802
 - agents for, 802
 - in combination regimens, 802
 - fetal effects of, 802
 - maternal effects of, 802
- Bethesda System, 206
- Biofeedback, for bladder control in incontinence, 249
- Biopsy
 - bone marrow, in autoimmune thrombocytopenia, 317
 - of breast mass, 234
 - endometrial, and endometrial cancer screening, 267
 - liver, for hepatitis C diagnosis, 121
 - uterine, dilation and curettage for, 276
- Birth asphyxia, in macrosomic infants, 766
- Birth weight
 - factors affecting
 - constitutional, 766
 - environmental, 766
 - genetic, 766
 - hormonal, 766
 - metabolic, 766
 - predictors of, 725
 - prenatal care and, 725
 - prenatal estimation of, 766
- Bishop, Edward H., observations and suggestions on
 - induction of labor, 757
- Bishop score, 757
- Bladder
 - dysfunction. *See* Urinary incontinence
 - endometriosis in, 699
 - in males, 699
 - leak point pressure, 249
- Bladder neck suspension, percutaneous, safety and efficacy of, 939
- Bleeding. *See also* Hemorrhage
 - abnormal
 - with endometrial cancer, 267
 - endometriosis-related, 620
 - with leiomyomata, 196
 - in autoimmune thrombocytopenic purpura, 317
 - with early induced abortion, management of, 290
 - with heparin thromboprophylaxis, 895
 - intracranial, in autoimmune thrombocytopenic purpura, 317
 - mucocutaneous, in platelet dysfunction, 390
 - in thrombocytopenia, 327
 - uterine
 - abnormal, hysteroscopy for, 276
 - profuse, as contraindication to hysteroscopy, 276
 - vaginal, tocolytic therapy and, 802
- Bleeding disorders, platelet-type, evaluation for, 349
- Bleeding time, 390
 - laboratory evaluation of, 349
- Blood, peripheral, cytokines in, and endometriosis, 566
- Blood pressure. *See also* Hypertension
 - control, in HELLP syndrome, 532
 - in HELLP syndrome, 381
 - in hemolytic-uremic syndrome, 360
 - measurement of, 455
 - in pregnancy, 455
 - in thrombotic thrombocytopenic purpura, 360
- Bone densitometry, 876
 - in estrogen-deficient women, 876
 - for evaluation of bone mass changes in response to therapy, 876
 - in heparin-induced osteoporosis, 876
 - indications for, 876
 - in osteopenia, 876
 - in primary hyperparathyroidism, 876
 - radiographic, 876
 - with spinal roentgenographic abnormalities, 876
 - in steroid therapy, 876
 - techniques for, 876
- Bone loss
 - postmenopausal, prevention of, 863, 876
 - with steroid therapy, 876
 - treatment of, efficacy of, evaluation using bone densitometry, 876
- Bone marrow
 - biopsy, in autoimmune thrombocytopenia, 317
 - evaluation, in thrombocytopenia, 349
 - suppression, with parvovirus infection, 107
- Bone mass
 - age and, 876
 - measurement of, 876
 - postmenopausal, androgen replacement and, 883
 - response to therapy, evaluation using bone densitometry, 876
- Bone mineral density
 - and bone strength, 876
 - and fracture risk, 876
 - postmenopausal hormone replacement and, 883
- Bowel, hyperechoic, sonographic findings, 71
- Brachial plexus injury
 - with macrosomia and shoulder dystocia, 766
 - in macrosomic infant, 766
- BRCA1 and BRCA2 gene mutations, and breast/ovarian cancer syndrome, 267
- Breast(s)
 - abscesses in, 234
 - adenosis in, 234
 - apocrine metaplasia of, 234
 - atypical ductal hyperplasia in
 - cancer risk with, 234
 - ductal involvement by cells of, cancer risk with, 234
 - benign disease of. *See also* Fibrocystic change; Fibrocystic disease
 - classification of, 234
 - clinical features of, 234
 - diagnostic workup of, 234
 - evaluation of, 234
 - history-taking in, 234
 - nonproliferative, pathology of, 234
 - office management of, 234
 - pathology of, 234
 - prevalence of, 234

- proliferative, pathology of, 234
- symptom assessment in, 234
- terminology for, 234
- calcifications in, 234
- complex sclerosing lesions of, 234
- cystic change in, 234
- cysts in, gross, 234
- ductal carcinoma in situ
 - cancer risk with, 234
 - differential diagnosis of, 234
- ductal hyperplasia in, 234
 - atypical, 234
 - cancer risk with, 234
 - mild, 234
 - moderate and florid, 234
- examination of, 234
 - patient education about, 234
- fibroadenoma in, 234
- fibrocystic change in, 234
- fibrocystic disease of, 234
- fibrosis in, 234
- fibrotic change in, 234
- fibrous disease of, 234
- galactoceles in, 234
- infections of, 234
- inflammation of, 234
- intraductal papillomas in, 234
 - cancer risk with, 234
- lobular carcinoma in situ
 - cancer risk with, 234
 - differential diagnosis of, 234
- lobular hyperplasia in
 - atypical, 234
 - cancer risk with, 234
- lumps in
 - cyclic and noncyclic, 234
 - dominant, 234
- macrocysts in, 234
- mammary duct ectasia in, 234
- masses in
 - diagnosis of, 234
 - fine-needle aspiration of, 234
 - lumpectomy for, 234
 - magnetic resonance imaging of, 234
 - mammography for, 234
 - nuclear scan of, 234
 - open surgical biopsy of, 234
 - physical examination of, 234
 - stereotactic needle biopsy of, 234
 - ultrasound of, 234
- mastitis in
 - acute, in cystic disease, 234
 - intrinsic, 234
 - lactational, 234
 - periductal, 234
- in Mondor disease, 234
- nipple changes, evaluation and management of, 234
- nipple discharge from, 234
 - in benign disease, 234
 - with cancer, 234
 - surgically significant, 234
 - types of, 234
- nodularity of, 234
- nonproliferative benign disease of, 234
- pain in, cyclic and noncyclic, 234
- physical examination of, 234
- physiologic cyclic swelling and tenderness of, 234
- proliferative benign disease of, 234
 - atypical, 234
 - without atypia, 234
- radial scars in, 234
- sclerosing adenosis in, 234
 - cancer risk with, 234
- self-examination of, 234
- skin changes, evaluation and management of, 234
- subareolar abscess in, 234
- symptom assessment, 234
- Breast cancer
 - in breast/ovarian cancer syndrome, 267
 - diagnosis of, 234
 - epidemiology of, 863
 - estrogen receptors in, 863
 - incidence of, 234
 - misdiagnosis of, 234
 - mortality from, 234
 - nipple discharge with, 234
 - progesterone receptors in, 863
 - prognosis for
 - factors affecting, 863
 - hormone receptor status and, 863
 - risk assessment, 234
 - risk factors for, 234
 - risk of, pathology of biopsied lesion and, 234
 - screening for, 234
 - survivors, estrogen replacement therapy for, 863
- Breastfeeding
 - in autoimmune thrombocytopenic purpura, 317
 - and hepatitis C transmission, 121
- Breast Imaging Reporting and Data System, 234
- Breech presentation, vaginal birth after cesarean section with, 836
- Bruising, in thrombocytopenia, 327
- Brush
 - ectocervical, in cervical cancer screening, evaluation of, 922
 - endocervical, in cervical cancer screening, evaluation of, 922
- Burch colposuspension,
 - for genuine stress incontinence, 249, 939
 - laparoscopic, validity of, 939
- Buserelin acetate, for endometriosis, 620, 645
- Butoconazole
 - vaginal cream, as vulvar irritant, 221
 - for vulvovaginal candidiasis, 184
- CA 125, serum levels, and ovarian cancer screening, 267
- Calcitonin, for osteoporosis, 876
- Calcium, dietary supplementation with, in prevention of preeclampsia, 436
- Calcium channel blockers. *See also* Nicardipine; Nifedipine
 - tocolytic therapy using, 802
- Calcium oxalate crystals, and vulvar vestibulitis, 221
- Cancer
 - angiogenesis in, 902
 - breast. *See* Breast cancer
 - endometrial. *See* Endometrial cancer
 - gynecologic. *See* Gynecologic cancer
 - ovarian. *See* Ovarian cancer
 - penile, prevention of, circumcision and, 849

- vulvar. *See* Vulva, cancer of
- Candidiasis
 - and cyclic vulvovaginitis, 221
 - and vulvar vestibulitis, 221, 945
 - vulvovaginal, 184
 - chronic, management of, 184
 - complicated, management of, 184
 - diagnosis of, 184
 - incidence and prevalence of, 184
 - oral therapy for, 184
 - pathophysiology of, 184
 - predisposing factors, 184
 - in pregnancy, 184
 - recurrent, management of, 184
 - signs and symptoms of, 184
 - topical therapy for, 184
 - treatment of, 184
 - vulvar care measures for, 184
- Capsaicin, topical, for vulvar vestibulitis, 945
- Carbamazepine, lupus induced by, 381
- Carbon dioxide, insufflation, for uterine distention, 276
- Carbon dioxide laser treatment, for genital warts, 206
- Carcinoma, of endometriotic origin, 699
- Cardiac abnormalities, sonographic findings, 71
- Cardiac failure
 - beta-mimetic-induced, 802
 - in macrosomic infants, 766
- Cardiac output, in hypertension, 519
- Cardiomegaly, sonographic findings, 71
- Cardiovascular disease, postmenopausal
 - androgen replacement therapy and, 883
 - estrogen replacement therapy and, 863, 883
 - prevention of, 863, 883
- β -Carotene, serum, in preeclampsia, 436
- Cats, and toxoplasmosis, 81, 149
- Ceftriaxone, for syphilis, 97
- Cell-mediated immunity, abnormalities, with endometriosis, 586
- Central nervous system
 - endometriosis of, 699
 - malformations, with parvovirus infection, 107
- Cerebral blood flow
 - in hypertensive encephalopathy, 519
 - in preeclampsia, 479
 - in pregnancy, 479
- Cerebral blood velocity
 - in normal pregnancy
 - central hemodynamic indices and, 479
 - mean arterial pressure and, 479
 - in preeclampsia, 479
- Cerebral edema, in macrosomic infants, 766
- Cerebral hemodynamics
 - in normal pregnancy, 479
 - in preeclampsia, 479
- Cerebral perfusion pressure
 - estimation of, 479
 - in normal pregnancy, 479
 - in preeclampsia, 479
 - high, management protocol for, 479
 - low, management protocol for, 479
 - magnesium sulfate therapy and, 479
 - management protocol for, 479
 - nimodipine therapy and, 479
 - normal, management protocol for, 479
- Cerebral vasculature, Doppler ultrasound studies of, indices for, 479
- Cerebral ventriculomegaly, sonographic findings, 71
- Cervex brush, in cervical cancer screening, evaluation of, 922
- Cervical cancer
 - adenocarcinoma in situ, management of, 916
 - as contraindication to hysteroscopy, 276
 - HPV infection and, 206, 267, 849
 - microinvasive squamous, management of, 916
 - prevention, male circumcision and, 849
 - risk factors for, 267
 - screening for. *See* Cervical cancer screening
- Cervical cancer screening, 267
 - conventional smears for
 - with adjunctive reinterpretation of negative smears, evaluation of, 922
 - with computerized interpretation
 - effectiveness of, studies of, 922
 - efficacy of, studies of, 922
 - sensitivity of, studies of, 922
 - specificity of, studies of, 922
 - efficacy and effectiveness of, evaluation of, 922
 - sensitivity and specificity of, evaluation of, 922
 - effects on woman's quality of life, 922
 - in HIV-infected (AIDS) patients, 267
 - liquid-based smears for
 - and conventional smears, comparison of sensitivity and specificity of, 922
 - sensitivity and specificity of, evaluation of, 922
 - modalities for, 267
 - in older women, 267
 - Pap smear for, 267
 - population-based
 - cost-effectiveness analysis of, 922
 - economics of, 922
 - important considerations for, 922
 - recommendations for, 267
 - sampling errors in, 922
 - smear interpretation in, errors in, 922
 - techniques, 922
 - techniques for, recommendations for, 922
 - tests for
 - effectiveness of, 922
 - efficacy of, 922
 - evaluation of, 922
 - sensitivity and specificity of, determination of relative changes in, 922
 - sensitivity of, 922
 - specificity of, 922
 - true sensitivity and specificity of, determination of, 922
 - two or more, comparing sensitivities and specificities of, 922
- Cervical intraepithelial neoplasia
 - HPV types associated with, 206
 - treatment of, 206
- Cervical pregnancy, 2, 9, 31
 - sonography in, 9
- Cervical ripening, prostaglandins for, 749
 - with vaginal birth after cesarean section, 836
- Cervicography, in HPV infection, 206
- Cervix, uterine
 - cancer of. *See* Cervical cancer
 - condition of

- Bishop score for, 757
- and elective induction of labor, 757
- cytology
 - and endometrial cancer screening, 267
 - specimen collection and processing for, 922
 - specimen interpretation for, 922
- endometriosis of, 699
- infection, as contraindication to hysteroscopy, 276
- in sexual response, 972
- Cesarean delivery. *See also* Vaginal birth after cesarean section
 - elective, with macrosomia, candidates for, 766
 - in HELLP syndrome, 381
 - for infants of diabetic mothers, 766
 - and neonatal herpes prevention, 134
 - cost-benefit analysis on, 134
 - rates of, 836
 - repeat, rates of, 836
 - risk of
 - with premature rupture of membranes, 749
 - timing of epidural placement and, 785
- trial of labor after
 - amnioinfusion in, 836
 - anesthesia for, 836
 - candidates for, 836
 - clinical considerations for, 836
 - complications of, 836
 - and delivery, 836
 - failure of, 836
 - management of, 836
 - monitoring during, 836
 - success rates for, 836
 - uterine dehiscence after, 836
 - uterine rupture after, 836
- Chancre, in primary syphilis, 97
- Chediak-Higashi syndrome, 390
- Childbirth. *See also* Vaginal birth after cesarean section
 - pelvic floor damage in, 820. *See also* Perineal trauma, childbirth-related
 - perineal trauma in, 820. *See also* Perineal trauma, childbirth-related
- Chlamydia* infection
 - and endometriosis, differentiation of, 664
 - and vulvar vestibulitis, 945
- Chlorpromazine, hepatotoxicity of, 381
- Cholestasis, drug-induced, 381
- Chromosomal abnormalities, and preeclampsia risk, 422
- Cigarette smoking, 24
- Circumcision, neonatal
 - anesthetic techniques for, 849
 - benefits of, critical analysis of, 849
 - and cervical cancer prevention, 849
 - cost-effectiveness of, 849
 - and foreskin retraction difficulties, 849
 - and HIV infection prevention, 849
 - and inflammatory penile disorders, 849
 - pain and distress inflicted by, 849
 - parental preferences regarding, factors affecting, 849
 - and penile cancer prevention, 849
 - and penile problems, 849
 - professional organizations' positions on, 849
 - rates of, 849
 - recommendation of
 - clinical experience and, 849
 - scientific evidence and, 849
 - risks of, critical analysis of, 849
 - and sexually transmitted disease prevention, 849
 - and sexual sensation and satisfaction, 849
 - surgical complications of, 849
 - surgical techniques for, 849
 - and urinary tract infection prevention, 849
- Cirrhosis, and hepatitis C, 121
- Clear-cell carcinoma, of endometriotic origin, 699
- Clindamycin, for bacterial vaginosis, 184
 - adverse effects and side effects of, 184
- Clinical recommendations, strength of, rating system for, 849, 972
- Clonidine
 - for acute severe hypertension in pregnancy, 519
 - for menopausal vasomotor symptoms, 863
 - for mild gestational hypertension/preeclampsia, 455
- Clotrimazole
 - vaginal cream, as vulvar irritant, 221
 - for vulvovaginal candidiasis, 184
- CMV. *See* Cytomegalovirus
- Coagulopathy
 - in HELLP syndrome, 532
 - and preeclampsia risk, 422
- Coitus, endometriosis-related pain and, 664
- Cold knife conization, and loop electrosurgical excision procedure, comparison of, 916
- Collagen
 - changes in, in injury and wound healing, 820
 - in connective tissue, 820
 - periurethral injections, for incontinence, 249
 - type I, 820
 - type III, 820
- Collagen receptor defects
 - diagnosis of, 390
 - pathophysiology of, 390
 - treatment of, 390
- Collagen vascular disease
 - differential diagnosis of, 381
 - and pregnancy, 551
- Color flow Doppler ultrasound
 - aliasing in, 902
 - artifacts in, 902
 - color gain for, 902
 - color priority for, 902
 - for ectopic pregnancy diagnosis, 39
 - flow velocity for, 902
 - imaging parameters for, 902
 - normal ovarian blood flow on, 902
 - in ovarian cancer diagnosis, 902
 - accuracy of, 902
 - in cluster or sequence of diagnostic tests, 902
 - receiver operator characteristic curves for, 902
 - resistive index for, 902
 - studies of
 - and comparison with gold standard of diagnosis, 902
 - evaluation of, 902
 - exclusion criteria for, 902
 - inclusion criteria for, 902
 - observer variation in, 902
 - patient sample for, 902
 - percent premenopausal patients in, 902
 - practice setting and, 902
 - reproducibility of results in, 902
 - sample size in, 902

- technology description in, 902
 - test characteristics in, 902
 - and treatment planning, 902
 - usefulness of, studies of, 902
- range ambiguity in, 902
- sample volume for, 902
- technology of, 902
- wall filters for, 902
- Colpocentesis, 9
- Colporrhaphy, anterior, for genuine stress incontinence, 249
- Colposcopy
 - indications for, 206
 - with vulvar vestibulitis, 221
- Complementary medicine, 306
- Complement fixation test, for toxoplasmosis diagnosis, 81
- Compression devices, for thromboprophylaxis, 895
- Compression stockings, for thromboprophylaxis, 895
- Computed tomographic scan, 9
- Condyloma
 - definition of, 206
 - HPV types associated with, 206
- Condyloma lata, 206
- Congenital anomalies, structural, and preeclampsia risk, 422
- Connective tissue
 - childbirth-related damage to, 820
 - composition of, 820
 - disorders, and genital prolapse, 820
- Cordocentesis
 - risks with, 59
 - for toxoplasmosis diagnosis, 81
- Cornual pregnancy, 2, 9
 - sonography in, 9
- Corpus luteum cyst, hemorrhagic, 9
- Corpus luteum insufficiency, with endometriosis, 586
- Corticosteroids
 - for HELLP syndrome, 532
 - for immune-associated pregnancy failure, 979
 - for thrombotic thrombocytopenic purpura, 551
 - for vulvar vestibulitis
 - oral administration of, 945
 - topical administration of, 945
- Counseling, with ultrasound screening in pregnancy, 737
- Creatine kinase, in diagnosis of ectopic pregnancy, 9
- Creatinine, serum, in preeclampsia, 455
- Cryotherapy
 - indications for, 916
 - and loop electrosurgical excision procedure, comparison of, 916
- Culdocentesis, 9
- Curettage
 - cervical, in cervical pregnancy, 2, 31
 - in diagnosis of ectopic pregnancy, 9
- Cyclic vulvovaginitis, 221
 - diagnosis of, 221
 - treatment of, 221
- Cyclophosphamide, for autoimmune thrombocytopenic purpura, 317
- Cyproterone acetate, for endometriosis, 620
- Cystocele, 249
- Cystourethropexy, safety and efficacy of, 939
- Cystourethroscopy, dynamic water, 249
- Cytokine production, and endometriosis, 566
- Cytolysis of vaginal epithelium, 221
- Cytomegalovirus
 - antibodies to, 81, 149
 - congenital. *See also* TORCH infections
 - adverse outcomes with, 59, 81
 - asymptomatic, 81
 - chemoprophylaxis for, 81
 - clinical findings, 81
 - developmental delay with, 81
 - hearing loss with, 59, 81
 - laboratory findings, 81
 - long-term sequelae, 59, 81
 - prevention of, 81
 - radiologic findings, 81
 - sequelae of, 59, 81
 - treatment for, 81
 - course of, 149
 - culture of, 59, 149
 - diagnosis of, 59, 149
 - disease and infection, difference between, 149
 - epidemiology of, 81, 149
 - and human immunodeficiency virus, 149
 - maternal infection
 - primary, 81
 - recurrent, 81
 - overview of, 81
 - prevention of, 149
 - retinitis caused by, 149
 - screening for, 149
 - sonographic evaluation of, 71
 - validity of, 71
 - transmission of, 81
 - treatment for, 81
 - vaccine for, 81
- Cytotoxic agents, direct injection of, 23
- Danazol
 - anabolic side effects of, 620
 - androgenic side effects of, 620, 645
 - for autoimmune thrombocytopenic purpura, 317
 - for endometriosis, 620
 - adverse effects and side effects of, 620
 - dosage and administration of, 620
 - and gastrointestinal involvement, 699
 - and related pain, 645, 664
 - results with, 620
 - and urinary tract involvement, 699
- Dapsone
 - for autoimmune thrombocytopenic purpura, 317
 - for toxoplasmosis, 149
- Darkfield microscope, for syphilis diagnosis, 97
- Deafness, with congenital cytomegalovirus, 81
- Death, leading causes of, in women, 306
- Deep venous thrombosis, in gynecologic surgical patients
 - heparin therapy for, 895
 - mechanical thromboprophylaxis for, 895
 - prevention of, 895
 - rates of, 895
 - risk factors for, 895
- Dehydroepiandrosterone
 - adverse effects and side effects of, 883
 - and bone density, 883
 - circulating levels of, postmenopausal changes in, 883

- Dehydroepiandrosterone sulfate, circulating levels of, postmenopausal changes in, 883
- Delivery. *See also* Cesarean delivery; Preterm delivery
in autoimmune thrombocytopenic purpura, 317
in HELLP syndrome, 381
anesthesia for, 381
timing of, 381
with idiopathic thrombocytopenic purpura of pregnancy, 327
management of
in Bernard-Soulier syndrome, 390
in gestational diabetes, 766
with macrosomia, 766
in von Willebrand disease, 390
in vaginal birth after cesarean section, 836
- Dermatitis, vulvar, 221
- Dermatoses, vulvar, 221
- Desmopressin (DDAVP), for von Willebrand disease, 390
- Detrol
adverse effects and side effects of, 249
for urinary incontinence, 249
- Detrusor function, physiology of, 249
- Detrusor hyperreflexia, urinary incontinence with, 249
- Detrusor instability
evaluation of patient for, 249
pathophysiology of, 249
- Developmental delay, with congenital cytomegalovirus, 81
- Dexamethasone, for HELLP syndrome, 532
- Dextran in dextrose, for uterine distention, 276
- DFA-Tp. *See* Direct fluorescent antibody stains
- DHEA. *See* Dehydroepiandrosterone
- DHEAS. *See* Dehydroepiandrosterone sulfate
- Diabetes insipidus, in HELLP syndrome, 381
- Diabetes mellitus. *See also* Gestational diabetes; Infants of diabetic mothers
and preeclampsia risk, 422
- Diagnostic algorithms, 9
- Diagnostic tests, criteria for, 957
- Diethylstilbestrol, 23
- Dihydralazine, and seizure prophylaxis, in preeclampsia/eclampsia, 507
- Dilation and curettage, advantages and disadvantages of, 276
- Direct fluorescent antibody stains (DFA-Tp), for syphilis diagnosis, 97
- Disseminated intravascular coagulation, 327
and HELLP syndrome, 381
in hemolytic-uremic syndrome, 360
in thrombotic thrombocytopenic purpura, 360
- Ditropan, for urinary incontinence, 249
- Diuretics
for preeclampsia, 455
in prevention of preeclampsia, 436
- Donor insemination
fecundity rates, in endometriosis patients, 586
and preeclampsia, 422
- Doppler effect, 902
- Doppler ultrasound
for ectopic pregnancy diagnosis, 39
orbital
intraobserver variation in, 479
in normal pregnancy and preeclampsia, 479
techniques, 479
in ovarian cancer diagnosis, 902
transcranial
compression testing technique, 479
confounding influences on, 479
estimation of arterial and arteriolar constriction from, 479
intraobserver variation in, 479
limitations of, 479
in normal pregnancy and preeclampsia, 479
pulse pressure area index, 479
pulse velocity area index, 479
techniques, 479
transtemporal approach for, 479
- Douching, vaginal, 24
- Doxycycline, for syphilis, 97
- Drug(s). *See also specific drug*
hepatotoxicity of, 381
- Dual-energy x-ray absorptiometry, for bone mass measurements, 876
- Dual-photon absorptiometry, for bone mass measurements, 876
- Ductus arteriosus, indomethacin and, 802
- Duphaston. *See* Dydrogesterone
- Dydrogesterone, for endometriosis, 620
- Dyes, as vulvar irritants, 221
- Dysesthetic vulvodynia. *See* Vulvodynia, dysesthetic
- Dysmenorrhea, endometriosis-related, 611, 620, 664
- Dyspareunia
endometriosis-related, 611, 620, 664
introital, 221
with vulvar vestibulitis, 945
- Dystocia
and brachial plexus injury, 766
diagnosis of, in trial of labor after cesarean delivery, 836
infants of diabetic mothers and, 766
macrosomia and, 766
- EBV (Epstein-Barr virus) infection, perinatal. *See* TORCH infections
- Echinocytes, in HELLP syndrome, 381
- Eclampsia. *See also* HELLP syndrome; Preeclampsia
brain-capillary leak in, 519
clinical presentation of, 519
diagnosis of, 507
differential diagnosis of, 551
frequency of, in women not receiving seizure prophylaxis, 507
and hypertensive encephalopathy, differentiation of, 519
management of, 470, 507
pathophysiology of, 507
prediction of, 507
risk of, in HELLP syndrome, 381
thrombocytopenia with, 327
- Eclamptic convulsions
prevention of, 507. *See also* Seizure prophylaxis
treatment of, 507
- Econazole nitrate, for vulvovaginal candidiasis, 184
- Ectopic pregnancy
bagel sign with, 39
chronic, 48
classification of, 9
color flow Doppler techniques for, 39
diagnosis of, 9, 39

- algorithms for, 9
- classification of implantation sites, 9
- computed tomography in, 9
- culdcentesis in, 9
- curettage in, 9
- dilatation in, 9
- endocrine markers in, 9
- history of, 9
- laparoscopy in, 9
- magnetic resonance imaging in, 9
- physical findings in, 9
- progesterone metabolites in, 9
- signs in, 9
- sonography in, 9
- symptoms in, 9
- expectant management of, 48
 - complications of, 48
 - criteria for, 48
 - follow-up, 48
 - reported experience of, 48
 - with low levels of β -hCG, 48
 - successful, 48
 - summary and recommendations, 48
- extratubal nidations in, 2
- incidence of, 2
 - by location, 21-22, 22f
- medical management of, 23, 48
 - hyperosmolar glucose in, 23, 39
 - outcomes with, 39
 - methotrexate in, 23, 39
 - complications of, 23
 - outcomes with, 39
 - for persistent ectopic pregnancy, 23
 - potassium chloride in, 23, 39
 - prostaglandins in, 23
- natural history of, 9
- pathogenesis of, 2
- persistent, 9, 31
 - methotrexate for, 23
 - progesterone measurement in, 9
- previous, 23
- risk factors for, 2, 22f
- salpingocentesis for, 39
- surgical management of, 31, 48
 - abdominal pregnancy in, 31
 - alternative to, 31
 - cervical pregnancy in, 31
 - conservative versus radical, 31
 - interstitial pregnancy in, 31
 - laparoscopy versus laparotomy, 31
 - ovarian pregnancy in, 31
 - persistent ectopic pregnancy from, 31
 - reproductive outcome, 31
 - role of, 23
 - tubal pregnancy, 31
 - tubal mass with, 39
 - tubal patency with, after expectant management of, 48
 - tubal pathology and, 22
 - tubal ring with, 39
 - tubal rupture with, 39
 - with expectant management of, 48
 - methotrexate for, 48
- ultrasound findings in, 9, 39
 - transvaginal, 39
- ultrasound-guided injection of, 39
- Edema
 - cerebral, in posterior circulation, 519
 - in preeclampsia, 436, 455
- Ehlers-Danlos syndrome, genital organ prolapse in, 820
- EL. See Erythema infectiosum
- Eicosanoids
 - peritoneal, with endometriosis, 586
 - in preeclampsia, 436
- Elastin, in connective tissue, 820
- Electrical stimulation, functional, for bladder control in incontinence, 249
- Electrocoagulation, of endometriotic implants, 645, 664
- Electromyographic feedback, for vulvar vestibulitis, 945
- Electrosurgery, for endometriosis, 633
- ELISA. See Enzyme-linked immunosorbent assay
- Embryo transfer, 24
- Encephalitis, toxoplasmic, and human immunodeficiency virus, 149
- Endocrine dysfunction, with endometriosis, 586
- Endocrine markers, in diagnosis of ectopic pregnancy, 9
- Endometrial ablation
 - for menstrual disorders, 939
 - microwave, safety and efficacy of, 939
 - thermal, safety and efficacy of, 939
- Endometrial antibodies, and endometriosis, 979
- Endometrial autoantibodies, with endometriosis, 586
- Endometrial biopsy, and endometrial cancer screening, 267
- Endometrial cancer
 - clinical manifestations of, 267
 - epidemiology of, 267, 863
 - estrogen receptors in, 863
 - prognosis for, factors affecting, 863
 - risk factors for, 267
 - screening for
 - modalities for, 267
 - recommendations for, 267
 - steroid receptors in, 863
 - survivors, estrogen replacement therapy for, 863
 - tamoxifen and, 267
- Endometrial cytology, and endometrial cancer screening, 267
- Endometrial polyps, treatment of, hysteroscopy for, 276
- Endometrial resection, for menstrual disorders, 939
- Endometriosis
 - of abdominal wall, 699
 - in males, 699
 - and adenomyosis, differentiation of, 664
 - aromatase production in, 566
 - and assisted reproductive technology, 687
 - asymptomatic, 645, 664
 - autoantibodies and, 979
 - in bladder, 699
 - in males, 699
 - of central nervous system, 699
 - cervical, 699
 - and *Chlamydia trachomatis*, differentiation of, 664
 - chronic pelvic pain and, 664
 - classification of, 611, 664, 687, 699
 - historical perspective on, 611
 - and infertility, 611
 - clinical presentation of, 620, 687
 - with coexistent disease, 664
 - combined medical and surgical treatment of, 620, 645
 - efficacy of, 645

- course of, 664
- cytokines and, 566
- deep lesions
 - detection of, 664
 - pain with, 645, 664
- definition of, 566, 645, 664
- diagnosis of, 664
 - delayed, 664
 - early, 664
 - missed, 664
- dysmenorrhea with, 664
- dyspareunia with, 664
- estrogen and progesterone receptors in
 - in pathogenesis, 566
 - and response to medical treatment, 645
- extrapelvic, 699
 - course of, 699
 - diagnosis of, 699
 - epidemiology of, 699
- of extraperitoneal genital tract, 699
- and focal tenderness after hysterectomy, 664
- gastrointestinal, 664, 699
- genetics of, 566
- histogenesis of, 566
 - coelomic metaplasia theory of, 566
 - composite theory of, 566
 - direct extension theory of, 566
 - embryonic rests theory of, 566
 - implantation theory of, 566
 - induction theory of, 566
 - lymphatic metastasis theory of, 566
 - vascular metastasis theory of, 566
- incidence of, 586, 620, 645, 699
- and infertility, 586, 620, 633, 645, 664
 - and classification of endometriosis, 611
- laparoscopy with, 645, 664
 - outcomes, 645
- lesions, typical and atypical, 645
- macrophage recruitment and, 566
- in males, 699
- malignant transformation of, 699
- medical treatment of, 620, 645, 664. *See also* Danazol; Gonadotropin-releasing hormone agonists/analogues
 - analgesics in, 620
 - antiprogestins in, 620
 - fecundity after, 620
 - hormone replacement therapy in, 620
 - modalities for, 620
 - options for, 620
 - and outcome of in vitro fertilization, 687
 - progestogens in, 620
 - pseudopregnancy in, 620
- and menopause, 664
- musculoskeletal, 699
- natural killer (NK) cell activity in, 566
- and pain, 611, 633, 645, 664. *See also* Pain; Pelvic pain
- pathogenesis of, 566, 645, 699
 - endometrial adhesion and invasion of peritoneum in, 566
 - local peritoneal and immune factors in, 566
 - matrix metalloproteinases in, 566
- pathophysiology of, 586
- patient concerns with, 664
 - and pelvic pain, staging, 645, 664
 - of peripheral nervous system, 699
 - persistent versus recurrent, 664
 - pregnancy and, 664, 699
 - progressive, 645, 664
 - pulmonary, 699
 - self-limited, 664
 - severity of
 - and infertility, 611
 - and outcome of assisted reproductive technology, 687
 - and pelvic pain, 645, 664
 - sites of involvement, 620, 664, 699
 - spontaneous regression of, 664
 - staging, 645, 664, 687
 - steroid receptors in
 - in pathogenesis, 566
 - and response to medical treatment, 645
 - stromal and glandular components, and response to medical treatment, 645
 - superficial lesions, pain with, 645, 664
 - surgical management of, 645, 664
 - approaches to, 664
 - by coagulation, 645, 664
 - efficacy of, 645
 - by excision, 645, 664
 - fecundity after, 586, 620, 633, 645
 - and fertility outcomes, 586, 633, 645, 687
 - by hysterectomy, 664
 - by laparoscopic uterine (uterosacral) nerve ablation, 633, 664
 - laparoscopy versus laparotomy for, 633, 664
 - by laser vaporization, 633, 645
 - and medical treatment, combined, 645
 - modalities for, 620
 - options for, 633
 - outcome data, evaluation of, 633
 - and outcome of assisted reproductive technology, 687
 - outcomes with, 633, 645
 - postoperative pain management for, 664
 - by presacral neurectomy, 633
 - principles and rationale for, 633
 - thoracic, 699
 - treatment of. *See also* Endometriosis, medical treatment of; Endometriosis, surgical management of
 - alternative medicine and, 664
 - indications for, 620, 664
 - medical and surgical, combined, 645
 - primary, 645, 664
 - prophylactic, 620
 - and reproductive goals of patient, 633
 - secondary, 664
 - tertiary, 664
 - of umbilicus, 699
 - of urinary tract, 699
 - vaginal, 699
- Endoscopic techniques, validity of, 939
- Endothelial injury, in HELLP syndrome, 381
- Endothelin, in preeclampsia, 381
- Endothelium, functions of, estrogen replacement therapy and, 883
- Enzyme-linked immunosorbent assay
 - for hepatitis C diagnosis, 121

- for parvovirus diagnosis, 107
- of platelet-associated IgG, in phase II antiplatelet antibody assay, 317
- for toxoplasmosis diagnosis, 81, 149, 163
- Epidural analgesia, intrapartum, 785. *See also* Regional anesthesia
 - advantages and disadvantages of, 785
 - complications of, 785
 - effects on uterine function, 785
 - and instrumental delivery, 785
 - and maternal fever during labor, 785
 - and oxytocin augmentation, 785
 - prospective trials of
 - comparing epidural with nonepidural analgesia, 785
 - comparing two epidural techniques, 785
 - retrospective studies of, 785
 - comparing epidural and nonepidural groups, 785
 - using historic control groups, 785
 - timing of, and risk of cesarean birth, 785
 - for trial of labor after cesarean delivery, 836
- Episiotomy
 - and childbirth-related perineal trauma, 820
 - lacerations with, versus lacerations without, 820
- Epstein-Barr virus infection, perinatal. *See* TORCH infections
- Erb's palsy, with macrosomic infant, 766
- ERT. *See* Estrogen replacement therapy
- Erythema, vulvar, 221
- Erythema infectiosum
 - distribution of, 107
 - incubation period of, 107
 - and parvovirus infection, 107
 - rash with, 107
- Erythrocyte abnormalities, in HELLP syndrome, 381
- Erythrocyte transfusion, in thrombotic microangiopathy, 360
- Erythromycin, for syphilis, 97
- Erythromycin estolate, hepatotoxicity of, 381
- Essential thrombocytosis, platelet dysfunction in, 349
- Estradiol
 - levels, with endometriosis, 586
 - serum, differential threshold to suppress endometriosis, 620
- Estratest, 883
- Estrogen
 - decreased levels of, and urinary incontinence, 249
 - receptors
 - in endometrial cancer, 863
 - in endometrial cells, 863
 - for urinary incontinence, 249
 - vaginal cream
 - for urinary incontinence, 249
 - as vulvar irritant, 221
- Estrogen/progestin combinations, for endometriosis, 620
 - in add-back therapy, 620
 - with urinary tract involvement, 699
- Estrogen replacement therapy
 - and androgen levels, 883
 - and androgen replacement, combined, postmenopausal benefits of, 883
 - and bone mass, 876
 - in breast cancer survivors, 863
 - cardiovascular benefits of, 863, 883
 - and endometrial cancer, 863
 - in endometrial cancer survivors, 863
 - and urinary tract endometriosis, 699
- Exercise, and preeclampsia risk, 422
- Factor V Leiden mutation, and preeclampsia risk, 422
- Failed abortion, management of, 290
- Fallopscopy
 - with coaxial catheter, safety and efficacy of, 939
 - with linear eversion catheter, safety and efficacy of, 939
- Famciclovir, for herpes, 134
- Fatty acids, n-3, dietary supplementation with, in preeclampsia, 436
- Fecal incontinence, childbirth-related injury and, 820
- Fetal alcohol syndrome, 725
- Fetal anomalies
 - tocolytic therapy and, 802
 - ultrasound as screening test for, 737
 - benefits of, 737
 - counseling with, 737
 - gestational age at examination and, 737
 - populations studied and, 737
 - sensitivity of, 737
 - setting and, 737
 - specificity of, 737
 - studies of, evaluation of, 737
- Fetal distress, tocolytic therapy for, 802
- Fetal growth restriction, sonographic findings, 71
- Fetal hydrops
 - intrauterine fetal transfusion for, 107
 - nonimmune, with parvovirus infection, 107
 - with parvovirus infection, 107
 - management of, 107
 - sonographic findings, 71
- Fetal lung maturation
 - indicators of, in diabetic pregnancy, 766
 - steroid administration for, tocolytic therapy and, 802
- Fetal weight. *See also* Birth weight; Macrosomia
 - estimation of, 766
- Fetus, large. *See* Macrosomia
- Fever, maternal, during labor, epidural analgesia and, 785
- Fibrocystic change, in breast, 234
 - variants of, 234
- Fibrocystic disease, of breast, 234
 - variants of, 234
- Fimbrial pregnancy, 9
- Fine-needle aspiration, of breast mass, 234
- Fish oil, dietary supplementation with, in preeclampsia, 436
- Flaviviridae, 121
- Fluconazole
 - drug interactions with, 184
 - for vulvar vestibulitis, oral administration of, 945
 - for vulvovaginal candidiasis, 184
- 5-Flucytosine, for recurrent vulvovaginitis, 184
- Fluid, low-viscosity, for uterine distention, 276
- Fluorescent treponemal antibody absorption test (FTA-Abs), for syphilis diagnosis, 97, 149
- 5-Fluorouracil
 - for genital warts, 206
 - intravaginal use, vestibulitis caused by, 221
- Follicular abnormalities, with endometriosis, 586
- Foot pump device, for thromboprophylaxis, 895

- Forceps delivery, and childbirth-related perineal trauma, 820
- Foscarnet, for congenital cytomegalovirus, 81
- Fracture(s)
- clavicular, in macrosomic infant, 766
 - risk of
 - bone mineral density and, 876
 - reduction, estrogen replacement therapy and, 876
 - vertebral, 876
- FTA-Abs. *See* Fluorescent treponemal antibody absorption test
- Furazolidone, for trichomoniasis, 184
- Galactocele, 234
- Galactorrhea, 234
- with endometriosis, 586
- Gallbladder, endometriosis in, 699
- Gamete intrafallopian transfer, for endometriosis-associated infertility, 687
- cost analysis for, 687
 - and in vitro fertilization, comparison of, 687
- Gancyclovir
- for congenital cytomegalovirus, 81
 - for cytomegalovirus retinitis, 149
 - use during pregnancy, safety of, 81
- Genital organ prolapse
- childbirth-related damage and, 820
 - in connective tissue disorders, 820
- Genital tract, extraperitoneal, endometriosis of, 699
- Gentian violet, for recurrent vulvovaginitis, 184
- Genuine stress incontinence
- definition of, 249
 - etiology of, 249
 - evaluation of patient for, 249
 - pathophysiology of, 249
 - treatment of
 - with Burch colposuspension, 249, 939
 - nonsurgical, 249
 - with paravaginal repair, 939
 - with periurethral injectables, 939
 - surgical, 249
- Gestational age
- determination of, 766
 - and fetal infection, 59
 - at ultrasound examination, and detection of fetal anomalies, 737
- Gestational diabetes
- excessive fetal growth in, 766
 - fetal lung maturity in, indicators of, 766
 - glycemic control in, 766
 - labor and delivery in, management of, 766
 - macrosomia in, 766
 - noncompliance in, 766
 - prevalence of, 766
- Gestational thrombocytopenia, 317, 327
- causes of, 327
 - definition of, 327
 - in hypertensive disorders of pregnancy, 327
- Gestrinone, for endometriosis, 620
- GIFT. *See* Gamete intrafallopian transfer
- Glanzmann's thrombasthenia, 349
- laboratory findings in, 390
 - pathophysiology of, 390
 - platelet aggregation patterns in, 349
 - pregnancy management in, 390
 - antepartum measures for, 390
 - intrapartum measures for, 390
 - postpartum measures for, 390
 - prenatal diagnosis of, 390
 - type 1, 390
 - type 2, 390
- Glucocorticoids
- for autoimmune thrombocytopenic purpura, 317
 - for fetal lung maturation, tocolytic therapy and, 802
 - for preeclampsia, 470
- Glucose, hyperosmolar, for ectopic pregnancy, 23, 39
- treatment outcomes with, 39
- Glucose intolerance
- beta-mimetic-induced, 802
 - and gestational diabetes, 766
 - and macrosomia, 766
 - prevalence of, 766
- Glutathione S-transferase alpha 1-1, plasma level, in HELLP syndrome, 381
- GnRH. *See* Gonadotropin-releasing hormone
- Gonadotropin-releasing hormone agonists/analogues
- add-back therapy, 620
 - adverse effects and side effects of, 620
 - and bone metabolism, 620
 - for endometriosis, 620, 645, 664
 - with gastrointestinal involvement, 699
 - for uterine leiomyomata, 196
- Gonorrhea, testing for, specificity and sensitivity of, 163
- Goserelin
- adverse effects and side effects of, 620
 - for endometriosis, 620, 645
- Graduated compression stockings, for thromboprophylaxis, 895
- Granulocyte-macrophage colony-stimulating factor expression, in endometriotic lesions, 566
- Gray platelet syndrome
- diagnosis of, 390
 - pathophysiology of, 390
 - pregnancy management in, 390
 - prenatal diagnosis of, 390
- Guillain-Turner syndrome, 766
- Gynecologic cancer, screening for, office procedures for, 267
- Gynevision, 664
- Haptoglobin, serum, in HELLP syndrome, 532
- Hart's line, 221
- hCG, 9
- after salpingocentesis, 39
- α -hCG, 9
- β -hCG, 9, 48
- after laparoscopic salpingostomy, 31
 - detection of, 9
 - diagnostic protocol for, 9
 - low level of, 9
 - outcomes for, 48
 - normal level of, 9
 - persistent ectopic pregnancy and, 9
 - sonography and, 9
- HCV. *See* Hepatitis C
- Headache, in preeclampsia, and cerebral perfusion, 479
- Health care. *See also* Primary care
- alternative, 306
 - complementary, 306
 - episodic, 306

- functional, 306
- predictive, 306
- preventive, 306
- types of, 306
- Health promotion, in prenatal care, 725
- Hearing loss, with congenital cytomegalovirus, 81
- Heart block, congenital, prevention of, IVIG for, 368
- Heavy metals, dietary supplementation with, in pre-eclampsia, 436
- HELLP syndrome, 381
 - classification of, 381, 532
 - clinical features of, 360, 381, 532, 551
 - complications of, 381
 - obstetric, 381
 - conservative management of, 381
 - definition of, 381
 - delivery in, 381
 - anesthesia for, 381
 - timing of, 381
 - diagnosis of, 381, 532, 551
 - antepartum, 532
 - postpartum, 532
 - differential diagnosis of, 381, 532, 551
 - disseminated intravascular coagulation and, 381
 - etiology of, 381
 - fetal assessment in, 532
 - fluid and electrolyte management in, 532
 - genetics of, 532
 - imitators of, 532
 - immunology of, 532
 - labor and delivery in, 532
 - laboratory findings in, 360, 381, 455, 532, 551
 - liver involvement in, 532
 - management of, 470, 532
 - blood pressure control in, 532
 - hemotherapy in, 532
 - postpartum, 532
 - 12-step approach to, 532
 - maternal assessment in, 532
 - maternal morbidity and mortality in, 381, 532
 - multiple organ system failure in, 532
 - partial, 381
 - pathophysiology of, 381, 532, 551
 - perinatal care in, 532
 - perinatal outcome in, 381, 532
 - platelet abnormalities in, 532
 - postpartum, 381
 - postpartum management of, 381, 455
 - preterm, 381
 - treatment of, 381
 - recurrence, 422
 - risk for, in future pregnancy, 532
 - red blood cell morphology in, 532
 - refractory, 532
 - renal compromise in, 532
 - risk factors for, 381
 - seizure prophylaxis in, 532
 - spectrum of disease in, 532
 - and subsequent pregnancy, preconceptional counseling about, 381
 - at term, 381
 - treatment of, 381
 - thrombocytopenia in, 327
 - treatment of, 381
- Hemagglutination, for toxoplasmosis diagnosis, 81, 163
- Hemizona assay, 957
- Hemodynamic monitoring
 - in acute severe hypertension in pregnancy, 519
 - invasive, in HELLP syndrome, 381
- Hemolysis, in HELLP syndrome, 381
- Hemolytic anemia
 - in hemolytic-uremic syndrome, 360
 - microangiopathic, 532, 551
 - in thrombotic thrombocytopenic purpura, 360
- Hemolytic-uremic syndrome. *See also* Thrombotic thrombocytopenic purpura
 - clinical features of, 360
 - diagnosis of, 360
 - differential diagnosis of, 360, 381, 532, 551
 - laboratory findings in, 360
 - obstetric outcome with, 360
 - pathophysiology of, 360
 - in pregnancy, 360
 - clinical presentation of, 360
 - recurrence of, 360
 - remission, definition of, 360
 - risk factors for, 360
 - treatment of, 360
- Hemoperitoneum
 - detection of, 9
 - laparoscopic treatment of, 31
- Hemophilia, and hepatitis C, 121
- Hemorrhage. *See also* Bleeding
 - with early induced abortion, management of, 290
 - intracranial
 - in neonatal alloimmune thrombocytopenia, 368
 - in neonatal autoimmune thrombocytopenia, 317
 - sequelae, 335
 - in thrombocytopenic fetus or neonate, 317, 335
- Hemostasis, platelets in, 349
- Hemothorax, catamenial, 699
- Heparin
 - in antiphospholipid syndrome, 368, 436
 - fractionated. *See* Heparin, low molecular weight
 - for immune-associated pregnancy failure, 979
 - low molecular weight
 - advantages of, 895
 - adverse effects and side effects of, 895
 - pharmacology of, 895
 - in thromboprophylaxis, 895
 - mini-dose, in thromboprophylaxis, 895
 - osteoporosis induced by, bone densitometry in, 876
 - pharmacology of, 895
 - in preeclampsia prevention, 436
 - thrombocytopenia caused by, 895
 - in thromboprophylaxis
 - adverse effects and side effects of, 895
 - dosage and administration in, 895
 - evidence for, 895
 - unfractionated
 - adverse effects and side effects of, 895
 - pharmacology of, 895
 - in thromboprophylaxis, 895
 - and warfarin, in thromboprophylaxis, comparison of, 895
- Hepatic disease, with parvovirus infection, 107
- Hepatitis, drug-induced, 381
- Hepatitis B, 59. *See also* TORCH infections
 - diagnostic testing for, 59
- Hepatitis C virus

- antibodies to, 121
- blood transfusions and, 121
- classification of, 121
- clinical manifestations of, 121
- diagnosis of, 121
- effects on newborn, 121
- effects on pregnancy, 121
- epidemiology of, 121
- extrahepatic manifestations of, 121
- genome, discovery of, 121
- genomic structure of, 121
- and hemophilia, 121
- and human immunodeficiency virus, 121
 - liver disease with, 121
- and liver disease, 121
- management of, 121
- in newborn, 121
 - course of, 121
 - screening for, 121
- occupational exposure to, 121
- perinatal consequences of, 121. *See also* TORCH infections
- prevalence of, 121
- transmission of, 121
 - and breastfeeding, 121
 - heterosexual, 121
 - by household contact, 121
 - in intravenous immunoglobulin therapy, 368
 - risk factors for, 121
 - sexual, 121
 - vertical, 121
 - in HIV mothers, 121
 - in HIV-negative mothers, 121
- treatment of, 121
 - costs of, 121
- virology of, 121
- Hepatocellular carcinoma, with hepatitis C, 121
- Hepatocellular injury, in HELLP syndrome, 381
- Hepatomegaly, sonographic findings, 71
- Hermansky-Pudlak syndrome, 390
- Hernia
 - broad ligament, 664
 - occult, 664
 - pain with, 664
 - sciatic, 664
 - Spigelian, 664
- Herpes
 - acyclovir for, 81
 - antiviral therapy for, 134
 - asymptomatic shedding and, 134, 149
 - acyclovir suppression and, 134
 - cesarean delivery for, cost-benefit analysis on, 134
 - clinical manifestations of, 149
 - complications of, 134
 - diagnosis of, 149
 - incidence of, 149
 - management of, ACOG guidelines for, 134
 - method of delivery and, 134
 - onset of, 149
 - perinatal management of, 134
 - prevention of, 149, 1345
 - recurrent, studies on, 134
 - sonographic evaluation of, 71
 - survival with, 134
 - transmission of, 134
 - transplacental, 134
 - uterine, 134
- Herpes simplex virus
 - antibodies to, 149
 - culture of, 59
 - direct antigen detection of, 59
 - and human immunodeficiency virus, 149
- Herpesvirus 6, perinatal infection. *See* TORCH infections
- Herpesvirus 8, perinatal infection. *See* TORCH infections
- Heterotopic pregnancy, 2, 9
- Hirsutism, androgen replacement therapy and, 883
- Histrelin, for endometriosis, 620
- HIV. *See* Human immunodeficiency virus
- Home visits, in prenatal care, 725
- Hormone receptors, functions of, 863
- Hormone replacement therapy. *See also* Androgen replacement therapy
 - benefits of, 863
 - in breast cancer survivors, 863
 - cardiovascular benefits of, 863, 883
 - in endometrial cancer survivors, 863
 - for endometriosis
 - in add-back therapy, 620
 - postmenopausal administration of, 620
 - postsurgical administration of, 620
 - for menopausal symptoms, 863, 883
 - for osteoporosis, 863
- Hot flashes
 - clonidine therapy for, 863
 - estrogen therapy for, 863
- HPV. *See* Human papillomavirus
- HRT. *See* Hormone replacement therapy
- HSV. *See* Herpes simplex virus
- Human B19 parvovirus. *See* Parvovirus infection
- Human chorionic gonadotropin. *See* hCG
- Human immunodeficiency virus. *See also* TORCH infections
 - antibodies, in intravenous immunoglobulin, 368
 - infection
 - cervical cancer screening in, 267
 - combination therapy for, 149
 - and cytomegalovirus, 149
 - epidemiology of, 149
 - and hepatitis C, 121
 - and herpes simplex virus, 149
 - and loop electrosurgical excision procedure, 916
 - and neurosyphilis, 149
 - prevention of, circumcision and, 849
 - prophylactic medication for, 149
 - and syphilis, 97, 149
 - treatment of, 97
 - thrombocytopenia in, 317
 - management of, 317
 - TORCH testing for, 149
 - and toxoplasmic encephalitis, 149
 - and toxoplasmosis, 81, 149
 - seropositivity for, after intravenous immunoglobulin therapy, 368
 - vertical transmission of, 59
- Human papillomavirus
 - characteristics of, 206
 - infection
 - and cervical cancer, 206, 267, 849

- cervicography in, 206
- clinical manifestations of, 206
- colposcopy in, 206
- cytologic evidence of, 206
- diagnosis of, 206
- immune system and, 206
- incidence of, 206
- malignant transformation of, 206
- prevalence of, 206
- prevention of, 206
- risk factors for, 206
- testing for, and detection of cervical neoplasia, 267
- transmission of, 206
- treatment of, 206, 221
- and vulvar vestibulitis, 221, 945
- warts caused by, treatment of, 206
- infectivity of, 206
- types of, associated with genital tract lesions, 206
- typing, 206
- Hutchinson's triad, with congenital syphilis, 97
- Hyaluronic acid, in HELLP syndrome, 381
- Hydatidiform mole, and preeclampsia risk, 422
- Hydralazine
 - for acute severe hypertension in pregnancy, 519
 - in expectant management of severe preeclampsia, 470
 - for hypertension, in HELLP syndrome, 381
 - for hypertension in HELLP syndrome, 532
 - lupus induced by, 381
 - for mild gestational hypertension/preeclampsia, 455
- Hydranencephaly, sonographic findings, 71
- Hydrocortisone, topical, for vulvar vestibulitis, 945
- Hydrops fetalis. *See* Fetal hydrops
- Hymenectomy, for vulvar vestibulitis, 221
- Hyperbilirubinemia, in macrosomic infants, 766
- Hyperglycemia, and macrosomia, 766
- Hyperhomocysteinemia, and preeclampsia risk, 422
- Hyperinsulinemia, fetal, and macrosomia, 766
- Hyperinsulinism, and macrosomia, 766
- Hyperosmolar glucose, for ectopic pregnancy, 23, 39
- treatment outcomes with, 39
- Hyperparathyroidism, primary
 - bone densitometry in, 876
 - epidemiology of, 876
- Hyperprolactinemia, with endometriosis, 586
- Hypertension. *See also* HELLP syndrome
 - acute severe
 - fetal assessment in, 519
 - intravenous fluid management in, 519
 - invasive hemodynamic monitoring in, 519
 - management of, 519
 - maternal evaluation in, 519
 - seizure prophylaxis in, 519
 - chronic
 - definition of, 519
 - and preeclampsia risk, 422
 - primary (essential), 519
 - secondary, 519
 - with superimposed preeclampsia, definition of, 519
 - gestational (transient)
 - definition of, 519
 - mild, antihypertensives for, 455
 - in HELLP syndrome, management of, 381
 - in pregnancy. *See also* Preeclampsia
 - classification of, 519
 - prevalence of, 436
 - proteinuric, before 20 weeks' gestation, 436
 - thrombocytopenia complicating, 327
- Hypertensive encephalopathy
 - brain-capillary leak in, 519
 - clinical presentation of, 519
 - diagnosis of, 507
 - and eclampsia, differentiation of, 519
 - management of, 519
 - pathophysiology of, 507, 519
- Hypocalcemia, in macrosomic infants, 766
- Hypoglycemia, in macrosomic infants, 766
- Hyskon, for uterine distention, 276
- Hysterectomy
 - abdominal, 939
 - decision analysis for, and role of cervix in sexual response, 972
 - for endometriosis, 633, 664
 - focal tenderness after, management of, 664
 - radical, laparoscopy in, 939
 - and studies of role of cervix in sexual response, 972
 - supracervical
 - and before-after study of role of cervix in sexual response, 972
 - versus total, and studies of role of cervix in sexual response, 972
 - for uterine leiomyomata, 196
 - vaginal, 939
 - laparoscopically assisted, 939
- Hysteroqram, abnormal, evaluation of, hysteroscopy for, 276
- Hysteroscopes
 - diagnostic, for office use, 276
 - flexible, 276
 - semirigid operative, 276
 - small-caliber (micro-hysteroscopes), 276
- Hysteroscopy
 - advantages and disadvantages of, 276
 - contraindications to
 - absolute, 276
 - relative, 276
 - diagnostic, office procedures for, 276
 - and endometrial cancer screening, 267
 - indications for, 276
 - instruments for
 - disinfection of, 276
 - maintenance of, 276
 - operative, office procedures for, 276
 - panoramic
 - patient selection for, 276
 - principles of, 276
 - technique for, 276
 - rationale for, 276
 - for resection of leiomyomata, 196
 - uterine distention for, methods of, 276
- Idiopathic thrombocytopenic purpura, 317, 327
 - bone marrow evaluation in, 349
 - and incidental thrombocytopenia of pregnancy, comparison of, 327
 - laboratory evaluation in, 349
 - of pregnancy, 327
 - diagnosis of, 327
 - fetal outcome with, 327
 - management of, 327
 - obstetric considerations with, 327

- IDM. *See* Infants of diabetic mothers
- IFN α . *See* Interferon
- Ileum, endometriosis in, 699
- Illicit drug use, maternal, and pregnancy outcome, 725
- Imipramine
 contraindications to, 249
 for urinary incontinence, 249
- Imiquimod, for human papillomavirus (HPV) infection, 206
- Immune modulators, for genital warts, 206
- Immune system. *See also* Antiphospholipid antibody syndrome
 and endometriosis, 566, 586
 fetal, response to infection, 59
 and HELLP syndrome, 532
 and HPV infection, 206
 ontogeny of, 59
 and preeclampsia, 422
 and reproductive function, 979
 self versus nonself recognition, 59
- Immunoblotting, in phase III antiplatelet antibody assay, 317
- Immunofluorescence
 for herpes simplex virus diagnosis, 149
 for toxoplasmosis diagnosis, 163
- Immunoglobulin
 intravenous. *See* Intravenous immunoglobulin
 for parvovirus infection, 107
 in perinatal infection, 59
 platelet-associated IgG
 in incidental thrombocytopenia of pregnancy, 327
 measurement of, 317
 in phase II antiplatelet antibody assay, 317
- Immunoperoxidase techniques, for herpes simplex virus diagnosis, 149
- Immunoprecipitation, in phase III antiplatelet antibody assay, 317
- Immunosuppressed patient, cervical cancer screening in, 267
- Immunosuppressive therapy
 for autoimmune thrombocytopenic purpura, 317
 for HELLP syndrome, 381
 for hemolytic-uremic syndrome, 360
 for thrombotic thrombocytopenic purpura, 360
- Implantation sites, classification of, 9
- Incomplete abortion, management of, 290
- Incontinence, urinary. *See* Urinary incontinence
- Indirect fluorescent antibody test, for toxoplasmosis diagnosis, 81, 149
- Indirect hemagglutination test, for toxoplasmosis diagnosis, 81
- Indomethacin, tocolytic therapy using, 802
 administration of, 802
 in combination regimens, 802
 fetal effects of, 802
 maternal effects of, 802
- Infants of diabetic mothers
 anthropometric findings in, 766
 asymmetric overgrowth in, 766
 delivery of, 766
 macrosomia in, 766
 perinatal outcomes for, 766
 pulmonary maturity of, indicators of, 766
 shoulder dystocia in, 766
- Infection
 with failed trial of labor after cesarean section, 836
 fetal
 gestational age and, 59
 maternal immunoglobulins and, 59
 pathogenesis of, 59
 intra-amniotic, risk of, with premature rupture of membranes, 749
 neonatal, risk of, with premature rupture of membranes, 749
 perinatal
 detection of, 59
 diagnosis of, difficulties in, 59
 maternal serologic response to, 59
 pathophysiology of, 59
 prevention of, 59
 sequelae, 59
- Infertility
 autoantibodies and, 979
 definition of, 979
 as ectopic pregnancy risk factor, 2, 9, 31
 endometriosis-associated, 586, 620, 633, 664. *See also* Assisted reproductive technologies
 with anatomic distortion and tubal obstruction, 586, 633
 with anovulation, corpus luteum insufficiency, and endocrine dysfunction, 586
 with autoimmunity/immune dysfunction, 586
 classification of endometriosis and, 611
 and fecundity after treatment, 586, 620, 633, 645
 with hyperprolactinemia/galactorrhea, 586
 with luteinized unruptured follicle syndrome, 586
 mechanisms of, 586, 645, 687
 mediators of, 586
 medical management of, 633
 with peritoneal eicosanoids, 586
 with peritoneal macrophages and peritoneal inflammatory response, 566, 586
 with spontaneous abortion, 586
 surgical management of, 633
 leiomyomata and, 196
 male
 definition of, 957
 evaluation for, 957
 semen analysis in, 957
 treatment of, as ectopic pregnancy risk factor, 2, 9, 31
 unexplained
 definition of, 979
 immunologic therapy for, 979
 zona pellucida antibodies and, 979
- Inflammatory disorders, with parvovirus infection, 107
- Inflammatory response, peritoneal, with endometriosis, 586
- Inguinal hernia, endometriosis in, 699
- Inhibin, in diagnosis of ectopic pregnancy, 9
- Insemination
 donor
 fecundity rates, in endometriosis patients, 586
 and preeclampsia, 422
 intrauterine, 687
 effect on endometriosis-associated infertility, 687
- Instrumental delivery
 and childbirth-related perineal trauma, 785, 820
 epidural analgesia and, 785
- Insulin resistance, and preeclampsia risk, 422
- Insulin sensitivity, pregnancy and, 766

- Intercourse, sexual, endometriosis-related pain and, 664
- Interferon
 for human papillomavirus (HPV) infection, 206, 221
 γ -IFN, and endometriosis, 566
 α -IFN, for hepatitis C, 121
 for vulvar vestibulitis, injections of, 945
- Interleukin(s), and endometriosis, 566
- Interstitial cystitis, vulvar vestibulitis and, 945
- Interstitial pregnancy, 2, 9, 31
 sonography in, 9
- Intestine(s), endometriosis in, 699
- Intra-abdominal calcifications, sonographic findings, 71
- Intracranial calcifications, sonographic findings, 71
- Intracranial hemorrhage
 in autoimmune thrombocytopenic purpura, 317
 in neonatal alloimmune thrombocytopenia, 368
 sequelae, 335
 in thrombocytopenic fetus or neonate, 335
- Intracytoplasmic sperm injection, outcome, endometriosis and, 687
- Intrauterine devices, 23
- Intrauterine fetal transfusions
 for fetal hydrops, 107
 for parvovirus infection, 107
- Intrauterine growth restriction, in preeclampsia, 455
- Intrauterine insemination, 687
 effect on endometriosis-associated infertility, 687
- Intrauterine pregnancy, with expectant management of ectopic pregnancy, 48
- Intravenous immunoglobulin
 adverse effects and side effects of, 368
 for antiphospholipid antibody syndrome, 368, 979
 for autoimmune thrombocytopenic purpura, 317, 368
 contraindications to, 368
 donor screening, 368
 for fetal alloimmune thrombocytopenia, 335
 for idiopathic thrombocytopenic purpura, in pregnancy, 327
 for immune-associated pregnancy failure, 979
 indications for, 368
 labeled indications for, 368
 mechanism of action of
 in autoimmune thrombocytopenic purpura, 368
 in neonatal alloimmune thrombocytopenia, 368
 for neonatal alloimmune thrombocytopenia, 368
 off label uses of, 368
 preparation of, 368
 prophylactic, for congenital heart block, 368
 for Rh isoimmunization, 368
 safety of, 368
 standards for, 368
 for thrombotic thrombocytopenic purpura, 368
- Intral Bladder Neck Support Prosthesis, for bladder control in incontinence, 249
- In vitro fertilization, 687
 for endometriosis-associated infertility and GIFT, comparison of, 687
 outcomes, 687
 effect of endometriomas on, 687
 effect of endometriosis on, 687
 with preceding medical therapy of endometriosis, 687
 pregnancy rates with, 687
 failure of, autoantibodies and, 979
 immune-directed therapy and, 979
- patients, prevalence of phospholipid antibodies in, 979
- Irritable bowel syndrome
 and chronic pelvic pain, 664
 diagnostic criteria for, 664
 treatment of, 664
- Isoniazid, hepatotoxicity of, 381
- Isthmic pregnancy, 9
- Itraconazole, for vulvovaginal candidiasis, 184
- IVF. *See* In vitro fertilization
- IVIG. *See* Intravenous immunoglobulin
- Jarisch-Herxheimer reaction, and syphilis treatment, 97
- Kegel exercises, for bladder control in incontinence, 249
- Ketoconazole, for vulvovaginal candidiasis, 184
- Kidney disorders
 in HELLP syndrome, 532
 and preeclampsia risk, 422
- endometriosis in, 699
- failure
 in HELLP syndrome, 381
 in hemolytic-uremic syndrome, 360
 in thrombotic thrombocytopenic purpura, 360
- Labetalol
 for acute severe hypertension in pregnancy, 519
 in expectant management of severe preeclampsia, 470
 for hypertension, in HELLP syndrome, 381
 for hypertension in HELLP syndrome, 532
 lupus induced by, 381
 for mild gestational hypertension/preeclampsia, 455
- Labor. *See also* Cesarean delivery, trial of labor after duration of
 epidural analgesia and, 785
 induction of labor and, 757
 in multiparas, 757
 in nulliparas, 757
 epidural analgesia during, 785
 induction of
 and duration of labor, 757
 elective, 757
 benefits of, 757
 Bishop's observations and suggestions on, 757
 candidates for, 757
 cervical condition and, 757
 complications of, 757
 methods for, 757
 recommended procedure for, 757
 risks of, 757
 studies of, 757
 term pregnancy and, 757
 indicated, 757
 with macrosomia, 766
 in nulliparas, 757
 in parous women, 757
 for post-term pregnancy, routine ultrasound in pregnancy and, 737
 with premature rupture of membranes, 749
 rates of, routine ultrasound in pregnancy and, 737
 softly indicated, 757
 with vaginal birth after cesarean section, 836
 management of, with vaginal birth after cesarean section, 836
 maternal fever during, epidural analgesia and, 785
 premature

- causes of, 802
- and preterm birth, 802
- and uterine irritability, differentiation of, 802
- second stage of, length of, and childbirth-related perineal trauma, 820
- spontaneous, with macrosomia, 766
- Lactate dehydrogenase
 - in HELLP syndrome, 381
 - serum, in HELLP syndrome, 532
- Lactobacillus*, and vulvovaginitis, 221
- Laparoscopic colposuspension, 939
- Laparoscopic uterine (uterosacral) nerve ablation, for endometriosis, 633, 664
- Laparoscopically assisted vaginal hysterectomy (LAVH), 939
- Laparoscopy, 9, 31
 - for abdominal pregnancy, 31
 - in Burch colposuspension, 939
 - for cryodestruction of leiomyomata, 196
 - diagnostic, 48
 - with endometriosis, 645, 664
 - normal (negative), with chronic pelvic pain, 664
 - laparotomy and, 31, 939
 - for myomectomy, 196, 939
 - operative (therapeutic), with endometriosis, 633, 645, 664
 - advantages and disadvantages of, 633
 - outcomes, 645
 - for pelvic lymphadenectomy, 939
 - for radical hysterectomy, 939
 - scars, endometriosis of, 699
 - for total hysterectomy, 939
 - treatment with, history of, 9
 - for vaginal hysterectomy, 939
 - validity of, 939
- Laparotomy
 - diagnosis with, history of, 9
 - for endometriosis, 633, 664
 - laparoscopy and, 31, 939
- Large-for-gestational-age fetus. *See also* Macrosomia
- antepartum surveillance for, 766
- perinatal morbidity and mortality in, 766
- Laser ablation, for menstrual disorders, 939
- Laser vaporization, of endometriotic implants, 633, 645
- LEEP. *See* Loop electrosurgical excision procedure
- Leiomyomata uteri
 - age-related incidence of, 196
 - ambulatory surgery treatments for, innovative, 196
 - bladder symptoms caused by, 196
 - body mass index and, 196
 - chromosomal abnormalities in, 196
 - clinical presentation of, 196
 - cryodestruction of, laparoscopic, 196
 - cytogenetic abnormalities in, 196
 - epidemiology of, 196
 - etiology of, 196
 - hormonal factors and, 196
 - hormonal treatment of, 196
 - hysteroscopic resection of, 196
 - and infertility, 196
 - intracavitary, management of, 196
 - menorrhagia with, 196
 - myomectomy for, indications for, 196
 - pelvic pain caused by, 196
 - pressure symptoms caused by, 196
 - prevention of, 196
 - risk factors for, 196
 - submucous
 - diagnosis of, 196
 - management of, 196
 - treatment of, hysteroscopy for, 276
 - subserosal, management of, 196
- Leukocyte infusion, for immune-associated pregnancy failure, 979
- Leukocytes
 - local (resident), in endometriosis, 566
 - peritoneal, in endometriosis, 566, 586
- Leuprolide acetate, for endometriosis, 620, 645
- Levonorgestrel intrauterine system, validity of, 939
- Libido, postmenopausal androgen replacement and, 883
- Lichen planus
 - clinical presentation of, 221
 - treatment of, 221
 - vulvodynia with, 221
- Lichen sclerosis
 - examination of patient with, 221
 - treatment of, 221
 - vulvodynia with, 221
- Lidocaine, topical, for vulvar vestibulitis, 945
- Lifestyle, as ectopic pregnancy risk factor, 24
- Lipoproteins
 - metabolism of, androgens and, 883
 - serum, estrogen replacement therapy and, 863, 883
- Liver. *See also* Acute fatty liver of pregnancy
- abnormalities, in HELLP syndrome, 381
- biopsy, for hepatitis C diagnosis, 121
- disease
 - and hepatitis C, 121
 - with human immunodeficiency virus, 121
 - platelet dysfunction in, 349
- dysfunction
 - androgen replacement therapy and, 883
 - in HELLP syndrome, 532
- hematoma, rupture, in HELLP syndrome, 381
- hemorrhage, in HELLP syndrome, 381, 532
- infarction, differential diagnosis of, 381
- parenchyma, endometriosis in, 699
- in preeclampsia, 455
- rupture, in HELLP syndrome, 532
- transplantation, for hepatitis C, 121
- Liver enzymes, elevation, in HELLP syndrome, 381
- Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase, deficiency, 551
- Loop electroexcision, for genital warts, 206
- Loop electrosurgical excision procedure
 - abuses of, 916
 - advantages of, 916
 - and cold knife conization, comparison of, 916
 - complications of, 916
 - contraindications to, 916
 - and cryotherapy, comparison of, 916
 - depth of, 916
 - electrode size for, 916
 - historical perspective on, 916
 - in HIV-infected (AIDS) patients, 916
 - indications for, 916
 - positive margins on, management of, 916
 - in pregnancy, 916
 - and pregnancy outcome, 916
 - thermal artifact in, 916

- uses of, 916
- Loop resection, for menstrual disorders, 939
- Loss ratio, 163
- Lubricating jelly, as vulvar irritant, 221
- Lung. *See also* Fetal lung maturation
 - parenchyma, endometriosis in, 699
- Lupron, for irritable bowel syndrome, 664
- Lupus, drug-induced, 381
- Lupus anticoagulant
 - in antiphospholipid syndrome, 368
 - and endometriosis, 979
 - laboratory detection of, 979
 - and preeclampsia risk, 422
- Luteinized unruptured follicle syndrome, with endometriosis, 586
- Luteinizing hormone, levels, with endometriosis, 586
- Lymphadenectomy, laparoscopic pelvic, 939
- Lymphocytes, and endometriosis, 566
- Lyndrenol, for endometriosis, 620
- Macroglossia, antepartum surveillance for, 766
- Macrophages
 - peritoneal, and endometriosis, 566, 586
 - recruitment, and endometriosis, 566
- Macrosomia. *See also* Large-for-gestational-age fetus
 - antepartum surveillance for, 766
 - anthropometric findings in, 766
 - in Beckwith-Wiedemann syndrome, 766
 - birth injuries in, 766
 - and brachial plexus injury, 766
 - and childbirth-related perineal trauma, 766
 - constitutional factors in, 766
 - definition of, 766
 - diagnosis of, 766
 - dystocia with, 766
 - elective cesarean delivery with, 766
 - environmental factors in, 766
 - fetal complications of, 766
 - genetic factors in, 766
 - in Guillain-Turner syndrome, 766
 - hormonal factors in, 766
 - incidence of, 766
 - intrapartum management of, 766
 - maternal age and, 766
 - maternal birth weight and, 766
 - maternal complications with, 766
 - maternal weight and, 766
 - metabolic abnormalities in, 766
 - metabolic factors in, 766
 - in nesidioblastosis, 766
 - parity and, 766
 - perinatal outcomes with, 766
 - in postterm pregnancy, 766
 - risk factors for, 766
 - in Sotos syndrome, 766
 - spontaneous versus induced labor with, 766
 - suspected, vaginal birth after cesarean section with, 836
 - in Weaver's syndrome, 766
- Magnesium
 - dietary supplementation with, in preeclampsia, 436
 - pharmacology of, 507
 - toxicity, 507
- Magnesium sulfate
 - adverse effects and side effects of, 507
 - for eclamptic convulsions, 507
 - pharmacology of, 507
 - in preeclampsia
 - effect on cerebral and orbital vessels, 479
 - effect on cerebral hemodynamics, 479
 - safety considerations with, 507
- for seizure prophylaxis
 - in acute severe hypertension in pregnancy, 519
 - efficacy of, 507
 - in HELLP syndrome, 381, 532
 - historical perspective on, 507
 - mode of action of, 507
 - in preeclampsia/eclampsia, 470, 507
- tocolytic therapy using
 - administration of, 802
 - adverse effects and side effects of, 802
 - beneficial effects of, 802
 - in combination regimens, 802
 - effectiveness of, 802
 - fetal effects of, 802
 - maternal side effects of, 802
 - mechanism of action of, 802
 - toxicity (overdose) of, 802
- Magnetic resonance imaging, 9
 - for abdominal pregnancy, 31
 - of breast mass, 234
 - cerebral, in eclampsia, 519
 - of uterus, advantages and disadvantages of, 276
- Mammography
 - abnormality seen on, evaluation and management of, 234
 - diagnostic, 234
 - of radial scars, 234
 - screening, 234
- March of Dimes, recommendations for prenatal care, 725
- Marfan's syndrome, genital organ prolapse in, 820
- Marshall-Marchetti-Krantz procedure, for genuine stress incontinence, 249
- Mastalgia, 234
- Mastitis
 - acute, in cystic disease, 234
 - intrinsic, 234
 - lactational, 234
 - periductal, 234
- Maternal serum alpha-fetoprotein, for parvovirus diagnosis, 107
- Matrix metalloproteinases, endometrial, 566
- Meckel's diverticulum, endometriosis in, 699
- Meconium
 - staining, of amniotic fluid, risks associated with, 766
 - thick, with postdates, risks associated with, 766
- Medical interventions, in prenatal care, 725
- Medications, hepatotoxicity of, 381
- Medroxyprogesterone acetate
 - for endometriosis, 620, 645
 - for menopausal vasomotor symptoms, 863
 - oral administration of, 620
 - parenteral administration of, 620
- Megace. *See* Megestrol acetate
- Megestrol acetate, for endometriosis, 620
- Men, endometriosis in, 699
- Menopause
 - androgen changes in, 883

- endogenous estrogen withdrawal in, symptoms of, 863
- endometriosis and, 664
- estrogen replacement after. *See* Estrogen replacement therapy
- mood changes in, postmenopausal androgen replacement and, 883
- psychological changes in, postmenopausal androgen replacement and, 883
- vasomotor symptoms in, postmenopausal androgen replacement and, 883
- Menorrhagia
 - endometrial destruction in, 939
 - with uterine leiomyomata, 196
- Menses, recurrent pneumothorax associated with, 699
- Menstruation, retrograde, 566, 645
- Mental retardation, with congenital cytomegalovirus, 81
- Mercury, for syphilis, 97
- Metabolic abnormalities, in macrosomic infant, 766
- Methotrexate, 48
 - complications of, 9, 23
 - direct injection of, 23, 39
 - effect on hCG, 39
 - follow-up evaluation with, 23
 - persistent ectopic pregnancy and, 23
 - pharmacology of, 23, 290
 - safeguards with, 23
 - side effects of, 23
 - management of, 290
 - single dose, 23
 - success rate, 31
 - teratogenicity of, 290
 - treatment outcomes with, 39
 - tubal cannulation and, 23
 - tubal rupture risk and, 48
 - variable dose, 23
- Methotrexate-misoprostol, abortion using, 290
 - clinical protocol for, 290
 - research findings on, 290
- Methyldopa
 - hepatotoxicity of, 381
 - lupus induced by, 381
 - for mild gestational hypertension/preeclampsia, 455
- Methylenetetrahydrofolate reductase, gene mutation, and preeclampsia risk, 422
- Metoprolol, for mild gestational hypertension/preeclampsia, 455
- Metronidazole
 - allergy to, management of, 184
 - for bacterial vaginosis, 184
 - adverse effects and side effects of, 184
 - contraindications to, 184
 - for trichomoniasis, 184
- Miconazole
 - vaginal cream, as vulvar irritant, 221
 - for vulvovaginal candidiasis, 184
- Microangiopathy
 - in HELLP syndrome. *See* HELLP syndrome
 - thrombotic. *See* Thrombotic microangiopathy
- Microcephaly, sonographic findings, 71
- Microhemagglutination assay-*Treponema pallidum* (MHA-TP), for syphilis diagnosis, 97, 149
- Micturition, neurophysiology of, 249
- Mifepristone
 - for endometriosis, 620
 - with gastrointestinal involvement, 699
 - pharmacology of, 290
- Mifepristone-misoprostol, abortion using, 290
- Mifepristone-prostaglandin, abortion using, 290
- Misoprostol
 - for labor induction, with premature rupture of membranes at term, 749
 - pharmacology of, 290
 - side effects of, management of, 290
- Mondor disease, 234
- Monocyte chemotactic protein-1, in endometriosis, 566
- Mood, postmenopausal androgen replacement and, 883
- Morphine, for focal tenderness after hysterectomy, 664
- MRI. *See* Magnetic resonance imaging
- MSAFP. *See* Maternal serum alpha-fetoprotein
- Multiple gestation
 - tocolytic therapy and, 802
 - vaginal birth after cesarean section with, 836
- Musculoskeletal system, endometriosis of, 699
- Myeloproliferative disorders, platelet dysfunction in, 349
- Myocardial inflammation, with parvovirus infection, 107
- Myocarditis, with parvovirus infection, 107
- Myomectomy
 - indications for, 196
 - laparoscopic, validity of, 939
- Nafarelin, for endometriosis, 620, 645
- Natural killer cell activity, in endometriosis, 566
- Necrotizing vasculitis, with parvovirus infection, 107
- Negative predictive value, of screening tests, 163, 737
- Neonatal alloimmune thrombocytopenia. *See* Alloimmune thrombocytopenia, neonatal
- Neonatal herpes disease. *See* Herpes
- Neonatal morbidity and mortality, routine ultrasound in pregnancy and, 737
- Neoplasia, of endometriotic origin, 699
- Nesidioblastosis
 - antepartum surveillance for, 766
 - pathophysiology of, 766
- Neural hyperplasia, and vulvar vestibulitis, 221
- Neurologic disorders, with parvovirus infection, 107
- Neurosyphilis, 97
 - diagnosis of, 97
 - and human immunodeficiency virus, 149
- Nicardipine
 - for acute severe hypertension in pregnancy, 519
 - for mild gestational hypertension/preeclampsia, 455
 - tocolytic therapy using, 802
- Nifedipine
 - for acute severe hypertension in pregnancy, 519
 - dosage and administration of, 519
 - adverse effects and side effects of, 519
 - in expectant management of severe preeclampsia, 470
 - hemodynamic effects of, 519
 - for hypertension in HELLP syndrome, 532
 - for mild gestational hypertension/preeclampsia, 455
 - off-label uses in pregnancy, 519
 - for preeclampsia, in postpartum management, 455, 532
 - and seizure prophylaxis, in preeclampsia/eclampsia, 507
 - tocolytic therapy using, 802
 - in combination regimens, 802

- Nimodipine
 effect on cerebral and orbital vessels in preeclampsia, 479
 effect on cerebral hemodynamics in preeclampsia, 479
 and seizure prophylaxis, in preeclampsia/eclampsia, 507
- Nitric oxide
 for HELLP syndrome, 532
 in prevention of preeclampsia, 436
- Nitrofurantoin
 hepatotoxicity of, 381
 lupus induced by, 381
- Nitroglycerin
 for acute severe hypertension in pregnancy, 519
 as tocolytic, 802
- Non-A, non-B hepatitis. *See* Hepatitis C
- Nonoxynol spermicide, vaginal cream, as vulvar irritant, 221
- Nonsteroidal anti-inflammatory drugs
 antiplatelet effects, 349, 390
 for endometriosis-related pain, 620
 tocolytic therapy using, 802
- Norethindrone
 with estrogens, combined, 664
 with organic bisphosphonate, combined, 664
- NPV. *See* Negative predictive value
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
- Nuclear imaging, of breast mass, 234
- Nulliparity, and preeclampsia, 422
- Nutrition, and pregnancy outcome, 725
- Nystatin, for vulvovaginal candidiasis, 184
- Obesity
 maternal, and macrosomia, 766
 and preeclampsia risk, 422
- Obstetrician-gynecologist, as primary care provider, 306
 ACOG publications on, 306
- Ocular disorders
 with congenital cytomegalovirus, 81
 with parvovirus infection, 107
- Omphalocele, antepartum surveillance for, 766
- Oocyte donation, and preeclampsia, 422
- Oral contraceptives
 for endometriosis-related pain, 645, 664
 in endometriosis treatment, 620
 and vulvovaginal candidiasis, 184
- Oral sex, and preeclampsia, 422
- Orbital circulation
 anatomy of, 479
 Doppler ultrasound assessment of
 in preeclampsia, 479
 in pregnancy, 479
- Osteopenia, bone densitometry in, 876
- Osteoporosis
 fractures due to, 876
 prevention of, 876
 heparin-induced, bone densitometry in, 876
 pathophysiology of, 876
 postmenopausal
 androgen replacement and, 883
 health care costs of, 863
 prevention of, 863, 876
 prevention of, 664
 spinal, bone densitometry in, 876
 treatment of, calcitonin for, 876
- Ovarian blood flow, on color flow Doppler ultrasound
 normal, 902
 resistive index for, 902
- Ovarian cancer
 angiogenesis in, 902
 in breast/ovarian cancer syndrome, 267
 diagnosis of, color flow Doppler ultrasound in, 902
 of endometriotic origin, 699
 family cancer patterns and, 267
 hereditary nonpolyposis colorectal cancer and, 267
 incidence of, 267
 in Lynch syndrome II, 267
 mortality with, 267
 prognosis for, 267
 risk factors for, 267
 screening for
 indications for, 267
 recommendations for, 267
 surgical staging of, 902
 treatment of, 902
- Ovarian endometriomas, management of, 633
- Ovarian function, with endometriosis, 586
- Ovarian hyperstimulation, 9
 controlled, 687
 effect on endometriosis-associated infertility, 687
- Ovarian pregnancy, 2, 9, 31
 sonography in, 9
- Ovarian remnant, 664
- Ovarian stimulation, progesterone level and, 9
- Ovarian tumor, benign versus malignant, differentiation of, 902
- Ovary(ies), normal, removal of, 939
- Ovulation induction, 2
- Oxalates, urinary, and vulvar vestibulitis, 945
- Oxprenolol, for mild gestational hypertension/preeclampsia, 455
- Oxybutynin chloride, for urinary incontinence, 249
- Oxytocin
 for induction of labor, 757
 and premature rupture of membranes, 749
 and vaginal birth after cesarean section, 836
- Pain. *See also* Dysmenorrhea; Dyspareunia; Pelvic pain;
 Vulvar vestibulitis; Vulvodynia
 endometriosis-related, 664
 empirical therapy for, 664
 with gastrointestinal involvement, 699
 management of, 645
 medication for, 620, 645, 664
 signs and symptoms of, 664
 staging, 664
 surgery for, 645, 664
 with urinary tract involvement, 699
 with hernia, 664
 menstrual, 664
 of neonatal circumcision, 849
 neonates' experience of, 849
 postmenopausal, endometriosis and, 664
 postoperative, management of, 664
- Pancreas, endometriosis in, 699
- Papnet, 206
 in cervical cancer screening, evaluation of, 922
- Pap test, 163
 accuracy of, improvement, techniques for, 206

- for cervical cancer screening, 267
- HPV infection detection by, 206
- techniques for, specificity and sensitivity of, 163
- Paraphimosis, 849
- Paravaginal repair, validity of, 939
- Paromomycin, for trichomoniasis, 184
- Parvovirus infection, 107. *See also* TORCH infections
 - antibodies to, 107
 - and arthralgia, 107
 - and arthritis, 107
 - and bone marrow suppression, 107
 - and chronic anemia
 - aplastic crisis in, 107
 - in immunocompromised patients, 107
 - clinical manifestations of, 107
 - conditions associated with, 107
 - diagnosis of, 107
 - criteria for, 107
 - false-positives, 107
 - repeat testing for, 107
 - effects of
 - on fetal organs, 107
 - on fetus, 107
 - on infant, 107
 - on pregnancy, 107
 - effects of pregnancy on, 107
 - epidemiology of, 107
 - and erythema infectiosum, 107
 - and erythroid aplasia, 107
 - evaluation of, 107
 - fetal, natural course of, 107
 - and fetal death, 107
 - fetal hydrops with, 107
 - management of, 107
 - nonimmune, 107
 - follow-up to, 107
 - hematologic abnormalities with, 107
 - hepatic disease with, 107
 - history of, 107
 - immunity to, 107
 - immunology of, 107
 - and intranuclear inclusions, 107
 - and intrauterine fetal transfusions, 107
 - management protocol for, 107
 - and myocarditis, 107
 - occupational exposure to, 107
 - ocular abnormalities with, 107
 - passive immunity to, 107
 - pathogenesis of, 107
 - pathologic findings of
 - in fetus, 107
 - in placenta, 107
 - pregnancy outcomes with, 107
 - prevention of, 107
 - seasonal pattern of, 107
 - teratogenicity of, 107
 - transmission of, 107
 - perinatal, 107
 - vaccine for, 107
 - virology of, 107
- PCR. *See* Polymerase chain reaction test
- Pedersen hypothesis, 766
- Pelvic examination, and ovarian cancer screening, 267
- Pelvic floor
 - childbirth-related damage to, 820. *See also* Perineal trauma, childbirth-related
 - denervation injury in, with subsequent re-innervation, 820
 - support/anatomic injury in, 820
- dysfunction
 - childbirth and, 820
 - etiology of, 820
- muscles, disorders of, and vulvar vestibulitis, 945
- Pelvic floor exercises
 - for bladder control in incontinence, 249
 - and mitigation of childbirth-related perineal damage
 - antepartum, 820
 - postpartum, 820
- Pelvic infection, after early induced abortion, management of, 290
- Pelvic mass, undiagnosed, management of, 196
- Pelvic organ(s)
 - prolapse
 - childbirth-related damage and, 820
 - in connective tissue disorders, 820
 - relaxation, evaluation for, 249
- Pelvic Organ Prolapse Quantification profile, 249
- Pelvic pain. *See also* Pain; Vulvar vestibulitis; Vulvodynia
 - acute, 664
 - caused by leiomyomata, 196
 - chronic, 664
 - associated conditions, 664
 - and endometriosis, 664
 - epidemiology of, 664
 - irritable bowel syndrome and, 664
 - normal (negative) laparoscopy with, 664
 - differential diagnosis of, 664
 - diffuse, versus focal, 664
 - endometriosis-related, 620, 664
 - alternative medicine and, 664
 - and classification (staging) of endometriosis, 611
 - and depth of infiltration, 633, 645, 664
 - integrated approach to, 664
 - management of, 633, 645, 664
 - mechanisms for, 645
 - and sexual intimacy, 664
 - signs and symptoms of, 664
 - staging, 645, 664
 - surgical management of, 633
 - focal
 - versus diffuse, 664
 - with fibrotic pathology, 664
 - sexual abuse and, 664
- Pelvic pressure, caused by leiomyomata, 196
- Pelvic support defects, site-specific quantitative description of, 249
- Peniciclovir, for herpes, 134
- Penicillin
 - allergy to, and syphilis treatment, 97
 - lupus induced by, 381
 - for syphilis, 81, 97
- Penile intraepithelial neoplasia, HPV types associated with, 206
- Penis
 - cancer of
 - HPV and, 849
 - prevention of, circumcision and, 849

- carcinoma in situ, prevention of, circumcision and, 849
- disorders of, prevention of, circumcision and, 849
- Perfumes, as vulvar irritants, 221
- Perinatal infections, sonographic findings, 71
- Perinatal morbidity and mortality
 - in large-for-gestational-age fetus, 766
 - routine ultrasound in pregnancy and, 737
- Perineal trauma, childbirth-related, 820
 - anteartum measures for mitigation of, 820
 - anterior compartment damage in, 820
 - denervation injury in, 820
 - follow-up for, 820
 - forceps and, 820
 - and genital organ prolapse, 820
 - intrapartum mitigation of, 820
 - macrosomia and, 766
 - management of, recommendations for, 820
 - mechanisms of damage in, 820
 - middle compartment damage in, 820
 - posterior compartment damage in, 820
 - postpartum measures for mitigation of, 820
 - prevention of, 820
 - rectal injury in, 820
 - site-specific, 820
 - and stress urinary incontinence, 820
 - support/anatomic injury in, 820
 - transient, 820
- Peripheral nervous system, endometriosis of, 699
- Peritoneal eicosanoids, with endometriosis, 586
- Peritoneal inflammatory response, with endometriosis, 586
- Peritoneal macrophages, with endometriosis, 586
- Periurethral injectables, validity of, 939
- Petechiae, in thrombocytopenia, 327
- Phenobarbital, lupus induced by, 381
- Phenytoin
 - hepatotoxicity of, 381
 - lupus induced by, 381
 - and seizure prophylaxis, in preeclampsia/eclampsia, 507
- Phimosi, 849
- Phosphatidic acid, autoantibodies to, and recurrent pregnancy loss, 979
- Phosphatidylethanolamine, autoantibodies to, and recurrent pregnancy loss, 979
- Phosphatidylglycerol, autoantibodies to, and recurrent pregnancy loss, 979
- Phosphatidylinositol, autoantibodies to, and recurrent pregnancy loss, 979
- Phosphatidylserine, autoantibodies to, and recurrent pregnancy loss, 979
- Pindolol, for mild gestational hypertension/preeclampsia, 455
- Placenta
 - abnormalities of, sonographic findings, 71
 - parvovirus infection in, 107
- Plasma
 - cryosupernatant, for thrombotic thrombocytopenic purpura, 551
 - exchange
 - for HELLP syndrome, in postpartum care, 381
 - for thrombotic thrombocytopenic purpura, 551
 - transfusions, for thrombotic thrombocytopenic purpura, 551
- Plasmapheresis
 - for hemolytic-uremic syndrome, 360
 - for thrombotic thrombocytopenic purpura, 360, 551
- Plasma volume expansion, in HELLP syndrome, 381
- Platelet count, 390
 - in autoimmune thrombocytopenic purpura, 317
 - fetal
 - in alloimmune thrombocytopenia, 335
 - in autoimmune thrombocytopenic purpura, 317
 - in incidental thrombocytopenia of pregnancy, 327
 - measurement of, 317
 - in twins, 317
 - in HELLP syndrome, 381, 532
 - in hemolytic-uremic syndrome, 360
 - in idiopathic thrombocytopenic purpura of pregnancy, 327
 - in incidental thrombocytopenia of pregnancy, 327
 - laboratory evaluation of, 349
 - normal range of, 327
 - spuriously low, in pregnancy, 317
 - in thrombocytopenia, 327
 - in thrombotic thrombocytopenic purpura, 360
- Platelet disorders, qualitative, 349
 - platelet aggregation patterns in, 349
- Platelets
 - activation, 349, 390
 - disorders of, 390
 - in phase I antiplatelet antibody assay, 317
 - adhesion, 349, 390
 - congenital disorders of, 390
 - aggregation, 349, 390
 - abnormalities, 360. *See also* Hemolytic-uremic syndrome; Thrombotic thrombocytopenic purpura
 - disorders of, 390
 - in inherited qualitative platelet disorders, 349
 - laboratory evaluation of, 349
 - laboratory studies of, 390
 - mediators of, 390
 - ristocetin-induced, 390
 - antigens
 - in alloimmune thrombocytopenia, 335, 368
 - ambiguous test results for, 335
 - in autoimmune thrombocytopenia purpura, 368
 - PI^{AI}, 335, 349, 368
 - typing, 335
 - clearance of, 327
 - development of, 349
 - dysfunction
 - acquired, 349
 - bleeding problems with, 390
 - congenital, 349, 390
 - inherited, 349, 390
 - laboratory studies with, 390
 - obstetric considerations with, 390
 - function, 349, 390
 - in autoimmune thrombocytopenic purpura, 317
 - drugs affecting, 349
 - laboratory evaluation of, 349
 - primary/secondary wave studies of, 390
 - glycoprotein receptors, 349
 - glycoproteins
 - in alloimmune thrombocytopenia, 335
 - antibody binding to, assays for, 317

- in autoimmune thrombocytopenic purpura, 317, 368
 - in Bernard-Soulier syndrome, 390
 - collagen receptor defects and, 390
 - in Glanzmann's thrombasthenia, 390
 - in idiopathic thrombocytopenic purpura of pregnancy, 327
 - α -granules, 349
 - deficiency of, 390
 - δ -granules, 349
 - deficiency of, 390
 - in hemostasis, 349
 - life span of, 327, 349
 - after fetal transfusion, 335
 - morphology of, 349
 - organelles in, 349
 - production of, 327
 - secretion, disorders of, 390. *See also* Storage pool disorder(s)
 - structure of, 349
- Platelet transfusions
- for autoimmune thrombocytopenic purpura, 317
 - contraindications to, in thrombotic microangiopathy, 360
- fetal
- for alloimmune thrombocytopenia, 335
 - maternal platelets for, 335
 - preparation of platelets for, 335
 - procedure for, 335
 - selection of platelets for, 335
- in HELLP syndrome, 532
- for thrombotic thrombocytopenic purpura, 551
- Pleura, endometriosis in, 699
- Pleural effusions, in preeclampsia, 455
- Pneumothorax, catamenial, 699
- Podofilox, for genital warts, 206
- Podophyllin, for genital warts, 206
- Polycythemia, in macrosomic infants, 766
- Polymerase chain reaction test
- for cytomegalovirus diagnosis, 149
 - for hepatitis C diagnosis, 121
 - for perinatal infection diagnosis, 59
 - for syphilis diagnosis, 97, 149
 - for toxoplasmosis diagnosis, 81, 149
- Positive predictive value, 163, 737
- effect of sensitivity and specificity on, 163
 - for extremely rare diseases, 163
 - hypothetical, calculation of, 163
 - for rare diseases, 163
 - sensitivity and specificity as hidden origin of, 163
 - for uncommon diseases, 163
- Postpartum care, in HELLP syndrome, 381
- Potassium chloride, for ectopic pregnancy, 39
- Potassium hydroxide, vaginal discharge test, 184
- PPV. *See* Positive predictive value
- Preconception care
- components of, 725
 - and pregnancy outcome, 725
- Prednisone, for autoimmune thrombocytopenic purpura, 317
- Preeclampsia. *See also* HELLP syndrome
- cerebral and orbital vessels in
 - magnesium sulfate and, 479
 - nimodipine and, 479
 - postpartum changes in, 479
 - cerebral circulation in, Doppler ultrasound assessment of, 479
 - cerebral hemodynamics in, 479
 - before and after treatment with magnesium sulfate or nimodipine, 479
 - cerebral perfusion pressure in, 479
 - management protocol for, 479
 - classification of, 436
 - clinical features of, 360
 - clinical presentation of, 436, 455
 - definition of, 436, 455, 519
 - diagnosis of, 436, 455
 - diagnostic criteria for, 436, 455
 - differential diagnosis of, 381, 532, 551
 - endothelin in, 381
 - epidemiology of, 436
 - etiology of, 422
 - family history of, 422
 - genetics of, 532
 - headache in, and cerebral perfusion, 479
 - hemodynamics of, 519
 - high-risk populations, identification of, 436
 - hypertension in, 436, 455
 - incidence of, 455, 470
 - indications for delivery in, 455
 - laboratory findings in, 360, 455
 - management of, 436, 519
 - ambulatory, 455
 - antihypertensives in, 455, 519
 - day care programs for, 455
 - fetal assessment in, 455, 519, 532
 - guidelines for, 455
 - hospitalization in, 455
 - hospital versus home, 455
 - intrapartum, 455
 - maternal assessment in, 455, 519, 532
 - outpatient, 455
 - perinatal outpatient monitoring service in, 455
 - postpartum, 455
 - traditional hospital approach, 455
 - volume expansion in, 519
 - mild, 436
 - management of, 455
 - multisystem effects of, 519
 - orbital circulation in, Doppler ultrasound assessment of, 479
 - paternal contribution to, 422
 - pathogenesis of, 422, 519
 - prevention of, 436
 - antihypertensives in, 436
 - bed rest in, 436
 - dietary sodium restriction in, 436
 - dietary supplementation in, 436
 - diuretics in, 436
 - low-dose aspirin in, 436
 - nonpharmacologic strategies for, 436
 - pharmacologic strategies for, 436
 - previous, and subsequent risk, 422
 - progression of, 455
 - and management, 470
 - recovery from, postpartum uterine curettage and, 532
 - risk factors for, 422, 436
 - age as, 422
 - exogenous, 422
 - interval between pregnancies as, 422

- non-partner-related, 422
- partner-related, 422
- preconceptual/chronic, 422
- pregnancy-associated, 422
- underlying disorders as, 422
- urinary tract infection as, 422
- screening for, 436
- seizure prophylaxis in, 470, 507. *See also* Seizure prophylaxis
- seizure therapy in, 507
- severe, 436
 - aggressive treatment of, 470
 - clinical presentation of, 455
 - diagnostic criteria for, 470
 - expectant management of, remote from term, 470
 - antenatal testing in, 470
 - candidates for, selection of, 470
 - contraindications to, 470
 - drug therapy in, 470
 - guidelines for, 470
 - long-term outcome with, 470
 - monitoring during, 470
 - outcomes with, 470
 - randomized studies of, 470
 - rationale for, 470
 - retrospective studies of, 470
 - setting for, 470
 - indications for delivery in, 470
- superimposed on chronic hypertension, 519
- thrombocytopenia with, 327
- and thrombotic microangiopathy, differentiation of, 360
- treatment of, 519
- Pregnancy
 - autoimmune thrombocytopenic purpura in, management of, 317
 - cerebral circulation in, Doppler ultrasound assessment of, 479
 - cervical, sonographic findings in, 9
 - contraindications to hysteroscopy in, 276
 - cornual, sonographic findings in, 9
 - ectopic. *See* Ectopic pregnancy
 - effects on endometriosis, 664
 - hemolytic-uremic syndrome in, 360
 - hypertension in, thrombocytopenia complicating, 327
 - idiopathic thrombocytopenic purpura of, 327
 - incidental thrombocytopenia of, 327
 - interstitial, sonographic findings in, 9
 - loop electrosurgical excision procedure in, 916
 - management of, routine ultrasound and, 737
 - multiple, and preeclampsia risk, 422
 - orbital circulation in, Doppler ultrasound assessment of, 479
 - outcome
 - demographic factors and, 725
 - loop electrosurgical excision procedure and, 916
 - maternal stress/anxiety and, 725
 - preconception care and, 725
 - prenatal care and, 725
 - routine ultrasound and, 737
 - ovarian, sonographic findings in, 9
 - post-term
 - definition of, 766
 - labor induction in, routine ultrasound in pregnancy and, 737
 - macrosomia in, 766
 - vaginal birth after cesarean section with, 836
 - postterm, antepartum surveillance for, 766
 - term, and elective induction of labor, 757
 - thrombotic thrombocytopenic purpura and, 360, 551
 - ultrasound in
 - as diagnostic modality, 737
 - routine use of, 737
 - safety of, 737
 - as screening test, 737
 - unintended, frequency of, 290
 - vulvovaginal candidiasis in, 184
- Pregnancy loss, recurrent
 - anticardiolipin antibodies and, 979
 - in antiphospholipid antibody syndrome, 368, 979
 - treatment with aspirin, heparin, and prednisone, 979
 - immune-directed therapy and, 979
 - immunologic therapy for, 979
 - leukocyte infusion for, 979
 - lupus anticoagulant and, 979
- Pregnancy rates
 - after endometriosis treatment, 586, 620, 633, 645
 - with assisted reproductive technology, for women with endometriosis, 687
 - with donor insemination, in endometriosis patients, 586
- Premature rupture of membranes
 - causes of, 802
 - definition of, 749
 - management of, historical perspective on, 749
 - outcome with, 749
 - and preterm birth, 802
 - at term, management of, 749
 - expectant, 749
 - future directions for, 749
 - meta-analyses of, 749
 - recommendations for, 749
 - TERMPROM study of, 749
- Prenatal care
 - benefits of, studies of, evaluation of, 725
 - components of, 725
 - definition of, 725
 - documentation of, 725
 - early, benefits of, 725
 - guidelines for, historical perspective on, 725
 - health promotion in, 725
 - historical perspective on, 725
 - home visits in, 725
 - interventions in, 725
 - March of Dimes recommendations for, 725
 - objectives of, 725
 - and pregnancy outcome, 725
 - risk assessment in, 725
 - use of, trends in, 725
 - visits for
 - ACOG recommendations for, 725
 - frequency of, 725
 - timing of, 725
- Presacral neurectomy, for endometriosis-related pain, 633, 664
- Preterm birth
 - maternal disease-related, 802
 - maternal HELLP syndrome and, 381
 - preterm labor-related, 802

- preterm rupture of membranes and, 802
- prevention of, 802
- rates of, prenatal care and, 725
- tocolytic therapy and, 802
- Preterm delivery
 - bacterial vaginosis and, 184
 - in hemolytic-uremic syndrome, 360
 - in thrombotic thrombocytopenic purpura, 360
 - trichomoniasis and, 184
- Primary care
 - definition of, 306
 - for episodic care patients, 306
 - for established patients, 306
 - history-taking in, 306
 - management plan in, 306
 - for new patients, 306
 - physical examination in, 306
 - for women, obstetrician-gynecologist's role in, 306
- Primipaternity, and preeclampsia, 422
- Problem-oriented medical record, 306
- Progesterone, 9
 - diagnostic protocol for, 9
 - levels, with endometriosis, 586
- Progestins
 - for endometriosis, 645
 - with urinary tract involvement, 699
 - for endometriosis-related pain, 620, 664
 - for menopausal vasomotor symptoms, 863
- Progestogens, for endometriosis, 620
- PROM. *See* Premature rupture of membranes
- Pronuclear stage transfer. *See* Zygote intrafallopian transfer
- Propantheline bromide (Probanthine), for urinary incontinence, 249
- Propylthiouracil, hepatotoxicity of, 381
- Prostaglandins, 23
 - for cervical ripening, 749
 - with vaginal birth after cesarean section, 836
 - endometriosis-associated, 586
 - in hemostasis, 349
- Prostanoids
 - in preeclampsia, 436
 - synthesis, inhibition by aspirin, 436
- Protein S deficiency, and preeclampsia risk, 422
- Proteinuria
 - definition of, 436, 455
 - in preeclampsia, 436, 455
- Provera. *See* Medroxyprogesterone acetate
- Pruritus vulvae, 221
- Pseudopregnancy, in endometriosis treatment, 620
- Psychosocial interventions, in prenatal care, 725
- Psychosocial strain, work-related, and preeclampsia risk, 422
- Pubis, endometriosis of, 699
- Pudendal nerve
 - anatomy of, 820
 - childbirth-related injury to, 820
 - and stress urinary incontinence, 820
 - electrophysiologic testing of, 820
- Pulmonary edema
 - beta-mimetic-induced, 802
 - in HELLP syndrome, 381
 - magnesium sulfate-induced, 802
- Purpura, in thrombocytopenia, 327
- Pyrimethamine, for toxoplasmosis, 81, 149
- Quantitative computed tomography, for bone mass measurements, 876
- R2323. *See* Gestrinone
- Rabbit infectivity test, for syphilis diagnosis, 71, 97
- Radioimmunoassay, of platelet-associated IgG, in phase II antiplatelet antibody assay, 317
- RADIUS trial, 737
- RANTES, in endometriosis, 566
- Rapid Plasma Reagin, for syphilis diagnosis, 97
- Recombinant immunosorbent assay, for hepatitis C diagnosis, 121
- Recommendations, clinical, strength of, rating system for, 849, 972
- Rectal injury, childbirth-related, 820
- Regional anesthesia
 - effects of
 - on fetal heart rate, 785
 - on umbilical cord blood gas levels, 785
 - on uteroplacental blood flow, 785
 - intrapartum. *See* Epidural analgesia
- Relaxation techniques, for pain relief, 664
- Reliance (device), for bladder control in incontinence, 249
- Renal. *See* Kidney
- Reproductive function, immune system and, 979
- Reproductive health screening, 725
- Research evidence, quality of, rating system for, 849, 972
- Reticulin, in connective tissue, 820
- Retinal detachment, in HELLP syndrome, 381
- Retinitis, cytomegalovirus, 149
- Reversible posterior leukoencephalopathy syndrome, 519
- Rh isoimmunization, intravenous immunoglobulin for, 368
- RIBA. *See* Recombinant immunosorbent assay
- Ristocetin cofactor activity, 390
- Ristocetin-induced platelet aggregation, 390
- RIT. *See* Rabbit infectivity test
- Ritodrine, tocolytic therapy using, 802
- Rollerball ablation, for menstrual disorders, 939
- RPR. *See* Rapid Plasma Reagin
- RU-486. *See also* Mifepristone
 - for uterine leiomyomata, 196
- Rubella
 - congenital, sequelae of, 59, 81
 - perinatal. *See also* TORCH infections
 - maternal serologic response to, 59
 - sonographic evaluation of, 71
 - vaccination for, 81
- Ruptured membranes. *See also* Premature rupture of membranes
 - tocolytic therapy and, 802
- Sabin-Feldman dye test, for toxoplasmosis diagnosis, 81, 149
- Sacral nerve stimulation, for urge incontinence, 939
- Safety and Efficacy Register of New Interventional Procedures, categorization of gynecological procedures, 939
- Salpingectomy, 48
 - interstitial pregnancy, risk factor for, 2
- Salpingocentesis
 - advantages of, over laparoscopy, 39

- for ectopic pregnancy, 39
- hCG titers following, 39
- risks of, 39
- transvaginal ultrasound-guided, 39
- treatment outcomes with, 39
- tubal damage with, 39
- Salpingography, therapeutic selective
 - with bicornual and tubal cannulation, 939
 - with guide-wire, 939
- Salpingo-oophorectomy, for endometriosis, 633
- Salpingostomy, 48
 - β -hCG level after, 9
 - interstitial pregnancy and, 31
 - laparoscopic
 - methotrexate and, systemic, 23
 - methotrexate versus, 31
 - linear, 31
 - methotrexate and, 23
 - persistent ectopic pregnancy and, 23
 - in tubal pregnancy, 31
- Scar tissue
 - laparoscopic, endometriosis in, 699
 - laparotomy, endometriosis in, 699
 - perineal, endometriosis in, 699
- Schizocytes, in HELLP syndrome, 381
- Screening
 - for alloimmune thrombocytopenia, 335
 - for breast cancer, 234
 - for cervical cancer, 267
 - for endometrial cancer, 267
 - for gynecologic cancer, office procedures for, 267
 - for ovarian cancer, 267
 - principles and rationale for, 306
 - requirements for, 737
 - targets for, 267
 - for vulvar cancer, 267
- Screening test(s)
 - accuracy of, 922
 - basic notation of, 163
 - effectiveness of
 - definition of, 922
 - determination of, 922
 - efficacy of
 - definition of, 922
 - determination of, 922
 - evaluation of, methodological issues in, 922
 - false-negative, 267, 737
 - false-positive, 267, 737
 - ideal, characteristics of, 737
 - negative predictive value of, 163, 737
 - positive predictive value of, 163, 737
 - calculation of, 163
 - sensitivity and specificity as hidden origin of, 163
 - reliability of, 737
 - reproducibility of, 737
 - requirements for, 737
 - sensitivity and specificity of, determination of relative changes in, 922
 - sensitivity of, 163, 267, 737, 922
 - specificity of, 163, 267, 737, 922
 - statistical considerations with, 163, 267, 922
 - true sensitivity and specificity of, determination of, 922
 - two or more, comparing sensitivities and specificities of, 922
 - validity of, 737, 922
- Seizure prophylaxis. *See also* Eclamptic convulsions
 - in acute severe hypertension in pregnancy, 519
 - in HELLP syndrome, 532
- magnesium sulfate for
 - in acute severe hypertension in pregnancy, 519
 - efficacy of, 507
 - in HELLP syndrome, 532
 - historical perspective on, 507
 - mode of action of, 507
- in preeclampsia/eclampsia, 470
 - antihypertensives and, 507
 - dihydralazine and, 507
 - nifedipine and, 507
 - nimodipine and, 507
 - phenytoin and, 507
- Semen analysis. *See also* Seminal fluid analysis
 - computer-assisted, 957
 - confounding variables in, 957
 - new tests for, 957
 - normal parameters for, WHO standards for, 957
 - tests for, clinical usefulness of, 957
- Seminal fluid analysis. *See also* Semen analysis
 - clinical usefulness of, 957
 - standard technique for, 957
 - validity of, 957
- Sensitivity
 - equal to specificity, effect on positive predictive value, 163
 - as hidden origin of positive predictive value, 163
 - and positive predictive value, 163
 - of screening test, 922
 - of screening tests, 163
- Sepsis
 - in HELLP syndrome, 381
 - in pregnancy
 - clinical presentation of, 551
 - diagnosis of, 551
 - management of, 551
 - organ system involvement in, 551
 - risk factors for, 551
- Sequential compression devices, for thromboprophylaxis, 895
- Sexual abuse, and pelvic pain, 664
- Sexuality, endometriosis-related pain and, 664
- Sexually transmitted disease, prevention of, in males,
 - circumcision and, 849
- Sexual response, role of cervix in, 972
 - evaluation of, randomized controlled trial for, 972
 - evidence for and against, critical analysis of, 972
 - studies of, evaluation of, 972
- Shoulder dystocia. *See* Dystocia
- Sickle cell disease, and preeclampsia risk, 422
- Sickle cell trait, and preeclampsia risk, 422
- Silicone injection, periurethral, safety and efficacy of, 939
- Silver impregnation technique, for syphilis diagnosis, 97
- Single-energy x-ray absorptiometry, for bone mass measurements, 876
- Single-photon absorptiometry, for bone mass measurements, 876
- Sling procedure, for genuine stress incontinence, 249
- Small intestine, endometriosis in, 699
- Smoking
 - and preeclampsia risk, 422

1032 INDEX

- and pregnancy outcome, 725
- SOAP notes, 306
- Sodium, dietary, restriction, in prevention of preeclampsia, 436
- Sodium nitroprusside
 - for acute severe hypertension in pregnancy, 519
 - for hypertension in HELLP syndrome, 532
- Sonography. *See* Ultrasound
- Sotos syndrome
 - antepartum surveillance for, 766
 - pathophysiology of, 766
- Spatulas, in cervical cancer screening, evaluation of, 922
- Special Supplemental Food Program for Women, Infants and Children, benefits of, 725
- Specificity
 - equal to sensitivity, effect on positive predictive value, 163
 - as hidden origin of positive predictive value, 163
 - and positive predictive value, 163
 - of screening test, 922
 - of screening tests, 163
- Sperm
 - analysis
 - confounding variables in, 957
 - tests for, clinical usefulness of, 957
 - exposure to, and preeclampsia, 422
 - function, tests of, 957
 - hyperactivation of, computer-assisted analysis of, 957
 - morphology
 - assessment of, 957
 - prognostic significance of, 957
 - movement characteristics
 - assessment of, 957
 - computer-assisted analysis of, 957
- Sperm antibodies
 - detection of
 - assays for, 957
 - immunobead binding test for, 957
 - mixed antiglobulin reaction for, 957
 - tests for
 - clinical usefulness of, 957
 - methods for, 957
 - prognostic value of, 957
 - validity of, 957
- Sperm penetration assay, 957
- Spherostomatocytes, in HELLP syndrome, 381
- Spine
 - osteoporosis of, bone densitometry in, 876
 - roentgenographic abnormalities of, bone densitometry with, 876
- Spiramycin, for toxoplasmosis, 81
- Spleen, accessory, 317
- Splenectomy
 - in autoimmune thrombocytopenic purpura, 317, 368
 - for idiopathic thrombocytopenic purpura, in pregnancy, 327
- Splenic implants, 664
- Splenomegaly, sonographic findings, 71
- Spontaneous abortion, with endometriosis, 586
- Squamous cell carcinoma, of endometriotic origin, 699
- Stereotactic needle biopsy, of breast mass, 234
- Steroid hormones
 - actions of, 863
 - receptors
 - functions of, 863
 - structure of, 863
- Steroid therapy
 - adverse effects and side effects of, 317
 - in autoimmune thrombocytopenic purpura, 317, 368
 - in pregnancy, 317
 - bone densitometry in, 876
 - bone loss with, 876
 - in fetal alloimmune thrombocytopenia, 335
 - for fetal lung maturation, tocolytic therapy and, 802
 - in HELLP syndrome, 381
 - in hemolytic-uremic syndrome, 360
 - in idiopathic thrombocytopenic purpura, in pregnancy, 327
 - in thrombotic thrombocytopenic purpura, 360
- Storage pool disorder(s)
 - $\alpha\delta$ -, 390
 - δ -, 390
 - acquired, 349, 390
 - congenital, 390
 - disorders associated with, prenatal diagnosis of, 390
- Streptococcus*, group B, neonatal infection, 59
- Stress
 - maternal, and pregnancy outcome, 725
 - and preeclampsia risk, 422
- Sulfonamides
 - hepatotoxicity of, 381
 - lupus induced by, 381
 - for toxoplasmosis, 81
- Surgery
 - for early abortion, 290
 - in ectopic pregnancy. *See* Ectopic pregnancy, surgical management of
 - for endometriosis. *See* Endometriosis, surgical management of
 - for genital warts, 206
 - for genuine stress incontinence, 249
 - for vulvar vestibulitis, 221
- Swab
 - ectocervical, in cervical cancer screening, evaluation of, 922
 - endocervical, in cervical cancer screening, evaluation of, 922
- Synarel. *See* Nafarelin
- Syphilis
 - cardiovascular, 97
 - clinical features of, 97
 - congenital, 97. *See also* TORCH infections
 - diagnosis of, 59, 97
 - diagnosis of, 59, 97, 149
 - direct detection methods, 97
 - false-negative tests, 97
 - false-positive tests, 97
 - non-treponemal tests, 97
 - sensitivity and specificity of tests for, 97
 - treponemal serologic tests, 97
 - epidemiology of, 97
 - fetal infection, 59
 - history of, 97
 - with human immunodeficiency virus, 97, 149
 - treatment of, 97, 149
 - immune response to, 149
 - late, 97
 - latent, 97
 - microbiology of, 97
 - pathogenesis of, 97

- pathophysiology of, 59
- in pregnancy, 97
 - treatment for, 81
 - treatment of
 - CDC guidelines for, 97
 - efficacy of, 97
- primary, 97
- reinfection with, 97
- risk factors for, 97
- screening for, 149
 - retesting in, 149
- secondary, 97
 - central nervous system involvement in, 97
 - clinical features of, 97
 - constitutional symptoms of, 97
 - dermatologic manifestations of, 97
 - genital tract involvement in, 97
 - sonographic evaluation of, 71
 - validity of, 71
- tertiary, 97
- transmission of, 97
 - fetal, 97
- treatment of, 97
 - failure of, 97
 - follow-up to, 97
 - and Jarisch-Herxheimer reaction, 97
 - with penicillin allergy, 97
- Systemic lupus erythematosus
 - and antiphospholipid antibody syndrome, 979
 - differential diagnosis of, 381, 551
 - and pregnancy, 551
- Systemic vascular resistance
 - in hypertension, 519
 - regulation of, 519
- Tamoxifen, and endometrial cancer, 267
- T-cells
 - fetal, 59
 - secretory products, and endometriosis, 566
- Terbutaline, tocolytic therapy using, 802
 - in combination regimens, 802
- Terconazole
 - vaginal cream, as vulvar irritant, 221
 - for vulvovaginal candidiasis, 184
- Termination of pregnancy. *See also* Abortion, spontaneous
 - cervical pregnancy, risk for, 2
- TERMPROM study, of premature rupture of membranes
 - at term
 - findings of, 749
 - secondary analyses from, 749
- Testosterone
 - circulating levels of, postmenopausal changes in, 883
 - postmenopausal replacement of, and libido, 883
- Tetracycline, for syphilis, 97
- Thiazide diuretics, contraindications to, 436
- ThinPrep 2000 System, in cervical cancer screening,
 - evaluation of, 922
- Thrombocytopenia
 - with absent radii, 390
 - antiplatelet antibody testing in, 349
 - in autoimmune thrombocytopenic purpura, 317
 - bleeding in, 327
 - bone marrow evaluation in, 317, 349
 - definition of, 327
 - with eclampsia, 327
 - fetal, in autoimmune thrombocytopenic purpura, 317, 368
 - gestational. *See* Gestational thrombocytopenia
 - in HELLP syndrome, 455, 532
 - in hemolytic-uremic syndrome, 360
 - heparin-induced, 317, 895
 - in HIV-infected (AIDS) patients, 317
 - management of, 317
 - in hypertensive disorders of pregnancy, 327
 - immune conditions associated with, 317
 - incidental, of pregnancy, 327
 - clinical characteristics of, 327
 - and idiopathic thrombocytopenic purpura, comparison of, 327
 - prevalence of, 327
 - with increased platelet destruction, 327
 - neonatal, with idiopathic thrombocytopenic purpura of pregnancy, 327
 - platelet aggregation studies in, 349
 - with platelet sequestration, 327
 - with platelet underproduction, 327
 - in preeclampsia, 327, 455
 - in pregnancy, 317. *See also* Gestational thrombocytopenia
 - thrombopoietin assays in, 349
 - in thrombotic thrombocytopenic purpura, 360
- Thromboembolism, in gynecologic surgical patients
 - heparin therapy for, 895
 - mechanical thromboprophylaxis for, 895
 - prevention of, 895
 - rates of, 895
 - risk factors for, 895
- Thrombopathy, platelet aggregation patterns in, 349
- Thrombophilic disorders, and preeclampsia risk, 422
- Thrombopoietin assays, in thrombocytopenia, 349
- Thromboprophylaxis
 - foot pump device for, 895
 - graduated compression stockings for, 895
 - heparin for, 895
 - mechanical, 895
 - sequential compression devices for, 895
- Thrombotic microangiopathy
 - clinical features of, 360
 - diagnosis of, 360
 - differential diagnosis of, 360
 - incidence of, 360
 - management of, 360. *See also* Hemolytic-uremic syndrome; Thrombotic thrombocytopenic purpura
 - natural history of, 360
 - and preeclampsia, differentiation of, 360
- Thrombotic thrombocytopenic purpura, 327
 - clinical features of, 360, 551
 - diagnosis of, 360
 - differential diagnosis of, 360, 381, 532, 551
 - etiology of, 551
 - IVIG for, 368
 - laboratory findings in, 360, 551
 - neurologic manifestations of, 360
 - obstetric outcome with, 360
 - pathophysiology of, 360, 551
 - in pregnancy, 360, 551
 - clinical presentation of, 360
 - recurrence of, 360, 551

- remission, definition of, 360
- risk factors for, 360
- treatment of, 360, 368
 - in pregnancy, 551
- Ticlopidine, antiplatelet effects, 349
- Tinidazole, for trichomoniasis, 184
- Tioconazole, for vulvovaginal candidiasis, 184
- Tissue inhibitors of metalloproteinases, effects on ectopic implantation of endometrium, 566
- TMP-SMZ, for toxoplasmosis, 149
- Tocolytic therapy
 - and advanced cervical dilatation, 802
 - agents for, 802
 - combination of, 802
 - benefits of, 802
 - candidates for, 802
 - chronic use of, 802
 - clinical considerations in, 802
 - duration of action of, 802
 - and fetal anomalies, 802
 - fetal assessment for, 802
 - for fetal distress, 802
 - maternal assessment for, 802
 - mechanism of action of, 802
 - and multiple gestation, 802
 - overdiagnosis of premature labor and, 802
 - principles and rationale for, 802
 - purpose of, 802
 - risk/benefit analysis for, 802
 - risks from, 802
 - and ruptured membranes, 802
 - and steroid administration for fetal lung maturation, 802
 - underlying disease masked by, 802
 - and vaginal bleeding, 802
 - weaning from, 802
- α -Tocopherol, serum, in preeclampsia, 436
- Tofranil. *See* Imipramine
- Tolterodine tartrate
 - adverse effects and side effects of, 249
 - for urinary incontinence, 249
- TORCH infections
 - diagnosis of, 59
 - in pregnancy, 59
 - prenatal, 59
 - testing for, 59
 - guidelines for, 149
 - in HIV-infected women, 149
 - onset of, identification of, 59
 - problems in, 59
 - reliability of, 59
 - validity of, 59
- Toxoplasma gondii*
 - antibodies to, 149
 - as predictor of CNS disease, 149
 - as predictor of toxoplasmosis encephalitis, 149
 - and cats, 81, 149
 - culture of, 59
 - distribution of, 81
 - and human immunodeficiency virus, 149
 - life cycle of, 59, 81, 163
- Toxoplasmic encephalitis, and human immunodeficiency virus, 149
- Toxoplasmosis
 - antibodies to, 81
 - clinical manifestations of, 81
 - congenital, 149
 - clinical findings, 81
 - prevalence of, 163
 - prevention of, 81
 - sequelae of, 81
 - diagnosis of, 59, 81, 149
 - accuracy of, 81
 - criteria for, 81
 - guidelines for, 149
 - retesting, 149
 - direct antigen detection of, 59
 - epidemiology of, 81
 - etiology of, 163
 - fetal, 59
 - and household pets, 81, 149
 - and human immunodeficiency virus, 81, 149
 - in immunocompromised patients, 81
 - in pregnancy, 59, 149
 - adverse outcomes with, 81
 - transmission of, 149
 - treatment for, 81
 - prevalence of, geographical differences in, 163
 - prevention of, 81, 163
 - hygienic measures, 81
 - recurrence of, prevention of, 149
 - risk factors for, 81
 - screening for, 81, 163
 - justification of, 163
 - loss ratio with, 163
 - specificity and sensitivity of, 163
 - in United States, 163
 - sequelae of, 163
 - sonographic findings in, 71, 81
 - validity of, 71
 - transmission of
 - human, 81
 - regional differences in, 81
 - treatment of, 81
 - adverse outcomes with, 81
- Transforming growth factor- β , and endometriosis, 566
- Transfusions
 - for aplastic crisis, 107
 - for chronic anemia, 107
 - and cytomegalovirus, 81
 - and hepatitis C, 121
 - intrauterine fetal
 - for fetal hydrops, 107
 - for parvovirus infection, 107
- Transvaginal ultrasound. *See* Ultrasound, transvaginal
- Treponema pallidum*, 97. *See also* Syphilis
- culture of, 59
- detection of, 97
- discovery of, 97
- Trichloroacetic acid, for genital warts, 206
- Trichomonas vaginalis*, 184
- Trichomoniasis
 - diagnosis of, 184
 - epidemiology of, 184
 - and preterm delivery, 184
 - recurrence of, 184
 - refractory, treatment of, 184
 - in sexually abused females, 184
 - signs and symptoms of, 184
 - treatment of, 184

- Tricyclic drugs (tricyclic antidepressants)
 contraindications to, 249
 for urinary incontinence, 249
- Triglycerides, serum, in preeclampsia, 436
- Triploidy, and preeclampsia risk, 422
- Trisomy 13, and preeclampsia risk, 422
- TRUST, for syphilis diagnosis, 97
- Tryptorelin, for endometriosis, 620
- Tubal embryo transfer. *See* Zygote intrafallopian transfer
- Tubal mass, with ectopic pregnancy, 39
- Tubal obstruction, with endometriosis, 586
- Tubal patency, after expectant management of ectopic pregnancy, 48
- Tubal pathology, ectopic pregnancy and, 22
- Tubal pregnancy, treatment of, 31
- Tubal ring, of ectopic pregnancy, 39
- Tubal rupture
 with ectopic pregnancy, 39
 with expectant management of ectopic pregnancy, 48
 methotrexate for, 48
- Tubal sterilization, 23
- Tumor necrosis factor- α , and endometriosis, 566
- Twin gestation
 tocolytic therapy and, 802
 vaginal birth after cesarean section with, 836
- Ultrasound
 in bone assessment, 876
 of breast mass, 234
 of childbirth-related posterior compartment damage, 820
 diagnostic, in pregnancy, 737
 for fetal weight estimation, 766
 fluid-enhanced, of uterus, advantages and disadvantages of, 276
 for parvovirus diagnosis, 107
 in pregnancy
 of amniotic fluid abnormalities, 71
 of cardiac abnormalities, 71
 of cerebral ventriculomegaly, 71
 in cytomegalovirus infection, 71
 for detection of large fetus, 766
 as diagnostic modality, 737
 for fetal anomalies, 737
 of fetal growth restriction, 71
 of fetal hydrops, 71
 with fetal infections, 71
 for gestational dating, 737
 β -hCG levels and, 9
 of hepatomegaly, 71
 in herpes simplex virus infection, 71
 of hydranencephaly, 71
 of hyperechoic bowel, 71
 of intra-abdominal calcifications, 71
 of intracranial calcifications, 71
 limitations of, 71
 of macrosomic fetus, 766
 of microcephaly, 71
 of placental abnormalities, 71
 predictive value of, 71
 for prenatal diagnosis of perinatal infection, 71
 routine use of, 737
 in rubella infection, 71
 safety of, 737
 as screening test, 737
 of splenomegaly, 71
 in syphilis, 71
 in toxoplasmosis, 71
 in twin gestation, 737
 validity of, 71
 in varicella infection, 71
 and pregnancy termination rates, 71
 safety of, in pregnancy, 737
 as screening test
 benefit in health outcomes with, 737
 counseling with, 737
 for fetal anomalies, 737
 in pregnancy, 737
 requirements for, 737
 sensitivity of, 737
 specificity of, 737
 validity of, 737
- transabdominal, 9
 β -hCG levels and, 9
- transvaginal, 9
 for abdominal pregnancy, 31
 advantages and disadvantages of, 276
 in diagnosis of ectopic pregnancy, 9
 and endometrial cancer screening, 267
 and ovarian cancer screening, 267
 utero-tubal contrast, safety and efficacy of, 939
- Ultrasound-guided injection, of ectopic pregnancy, 39
- Umbilicus, endometriosis of, 699
- United States Preventive Services Task Force, rating system for research evidence and resulting recommendations, 849, 972
- Ureaplasma*, and vulvar vestibulitis, 945
- Uremia, platelet dysfunction in, 349
- Ureter, endometriosis in, 699
- Urethral closure pressure profilometry, 249
- Urethrocystometrogram, 249
- Urethropexy, transvaginal needle, for genuine stress incontinence, 249
- Urge incontinence. *See also* Urinary incontinence
 treatment of, nonsurgical, 249
- Uric acid, serum, in preeclampsia, 455
- Urinalysis, in incontinent patient, 249
- Urinary continence, physiology of, 249
- Urinary incontinence
 age-related causes of, 249
 athletics-related, management of, 249
 definition of, 249
 with detrusor hyperreflexia, 249
 treatment of, 249
 with detrusor instability, treatment of, 249
 differential diagnosis of, 249
 estrogen-related causes of, 249
 evaluation of patient for, 249
 history-taking for, 249
 laboratory studies in, 249
 office assessment of, 249
 physical findings in, 249
 with sensory urgency, 249
 treatment of, 249
 stress. *See also* Genuine stress incontinence
 childbirth-related
 denervation injury and, 820
 mechanical trauma and, 820
 surgery for

- complications of, 249
 - techniques for, 249
- treatment of, 249
 - behavioral techniques for, 249
 - dietary measures in, 249
 - nonsurgical, 249
 - smoking cessation in, 249
 - surgical, 249
- urge, sacral nerve stimulation for, 939
- urinalysis in, 249
- urine culture in, 249
- urodynamic evaluation of patient with, 249
- workup of patient with, 249
- Urinary oxalates, and vulvar vestibulitis, 945
- Urinary tract
 - endometriosis in, 699
 - infection
 - in males, prevention of, circumcision and, 849
 - and preeclampsia risk, 422
- Urine culture, in incontinent patient, 249
- Urodynamic evaluation
 - complex, 249
 - simple, 249
- Uroflowmetry, electronic, 249
- USR, for syphilis diagnosis, 97
- Uterine bleeding
 - abnormal
 - endometriosis-related, 620
 - hysteroscopy for, 276
 - profuse, as contraindication to hysteroscopy, 276
- Uterine fibroids, embolization of, 939
- Uterine leiomyomata. *See* Leiomyomata uteri
- Uterus
 - adhesions in, treatment of, hysteroscopy for, 276
 - atony, postpartum, with macrosomic infant, 766
 - biopsy, dilation and curettage for, 276
 - dehiscence
 - after cesarean delivery, 836
 - repeat, risk for, 836
 - distention of
 - carbon dioxide insufflation for, 276
 - Dextran in dextrose (Hyskon) for, 276
 - for hysteroscopy, methods for, 276
 - low-viscosity fluids for, 276
 - endometrial sampling in, 276
 - infection, as contraindication to hysteroscopy, 276
 - lesions in, treatment of, hysteroscopy for, 276
 - perforation in early induced abortion, management of, 290
 - rupture of
 - with macrosomic infant, 766
 - management of future pregnancies after, 836
 - repeat, risk for, 836
 - with vaginal birth after cesarean section, 836
 - septate, treatment of, hysteroscopy for, 276
 - visualization of
 - fluid-enhanced sonography for, 276
 - hysteroscopy for, 276
 - magnetic resonance imaging for, 276
 - vaginal sonography for, 276
- Vacuum aspiration, for first-trimester abortion, 290
- Vacuum extraction, and childbirth-related perineal trauma, 820
- Vagina
 - anterior wall damage, childbirth-related, 820
 - endometriosis of, 699
 - normal flora of, 184
- Vaginal birth after cesarean section
 - ACOG guidelines for, 836
 - amnioinfusion in, 836
 - analgesia for, 836
 - benefits of, 836
 - with breech presentation, 836
 - candidates for, 836
 - clinical considerations for, 836
 - complications of, 836
 - contraindications to, 836
 - delivery in, 836
 - exploration of uterine cavity after, 836
 - facility requirements for, 836
 - historical perspective on, 836
 - infectious morbidity with, 836
 - informed consent for, 836
 - labor management in, 836
 - for macrosomic infants, complications of, 766
 - monitoring during, 836
 - with multiple scars, 836
 - with postterm pregnancy, 836
 - with previous low vertical incisions, 836
 - rates of, 836
 - selection criteria for, 836
 - success rates for, 836
 - with suspected macrosomia, 836
 - with twin gestation, 836
 - with unknown scars, 836
 - uterine rupture with, 836
- Vaginal bleeding, tocolytic therapy and, 802
- Vaginal creams, as vulvar irritants, 221
- Vaginal delivery, with macrosomia, 766
- Vaginal discharge
 - chronic, emotional effects of, 184
 - color of, 184
 - gram stain of, 184
 - microscopic findings in, 184
 - odor of, 184
 - pH of, 184
 - potassium hydroxide test (whiff test), 184
- Vaginal epithelium, cytotoxicity of, 221
- Vaginal hysterectomy, 939
 - and abdominal hysterectomy, comparison of, 939
 - laparoscopically assisted, 939
- Vaginal intraepithelial neoplasia, treatment of, 206
- Vaginal weighted cones, for bladder control in incontinence, 249
- Vaginismus, 221
- Vaginitis. *See also* Vulvovaginitis
 - causes of, 184
 - uncommon or rare, 184
 - prevalence of, 184
 - signs and symptoms of, 184
- Vaginitis, bacterial, 184
- Valacyclovir, for herpes, 134
- Varicella
 - culture of, 59
 - infection
 - fetal, 59. *See also* TORCH infections
 - sonographic evaluation of, 71

- Vascular endothelial growth factor, in endometriotic lesions, 566
- Vascular smooth muscle, function, estrogen replacement therapy and, 883
- Vasodilators. *See* Hydralazine; Nitroglycerin; Sodium nitroprusside
- VBAC. *See* Vaginal birth after cesarean section
- Venereal Disease Research Laboratory (VDRL), for syphilis diagnosis, 97, 149
- Vesica device, safety and efficacy of, 939
- Vesical leak point pressure, 249
- Vestibulectomy, for vulvar vestibulitis, 221, 945
- Vestibulitis. *See* Vulvar vestibulitis
- Vestibuloplasty, for vulvar vestibulitis, 221, 945
- Vidarabine, for herpes, 134
- Vinblastine, for autoimmune thrombocytopenic purpura, 317
- Vincristine, for autoimmune thrombocytopenic purpura, 317
- Viral infection, and vulvar vestibulitis, 945
- Visual impairment, with congenital cytomegalovirus, 59, 81
- Vitamin E, serum, in preeclampsia, 436
- Volume expansion, in preeclampsia, 519
- von Willebrand disease, 349
 - anesthesia considerations with, 390
 - delivery route in, 390
 - desmopressin (DDAVP) for, 390
 - diagnosis of, 390
 - differential diagnosis of, 390
 - epidemiology of, 390
 - family history in, 390
 - laboratory evaluation for, 349
 - laboratory findings in, 390
 - pathophysiology of, 390
 - personal history in, 390
 - platelet aggregation patterns in, 349
 - pregnancy management in, 390
 - antepartum measures for, 390
 - intrapartum measures for, 390
 - preconception measures for, 390
 - prenatal diagnosis of, 390
 - treatment of, 390
 - type 1, 390
 - type 2, 390
 - type 3, 390
- von Willebrand factor, 349
 - deficiency, 390
 - functions of, 390
 - multimeric analysis of, 390
 - in hemolytic-uremic syndrome, 360
 - in thrombocytopenia, 349
 - in thrombotic thrombocytopenic purpura, 360
- Vulva
 - anatomy of, 221
 - cancer of
 - epidemiology of, 267
 - screening for, 267
 - nociceptor pathways of, 945
- Vulvar dermatitis, 221
- Vulvar dermatoses, 221
- Vulvar hyperesthesia, 221
- Vulvar intraepithelial neoplasia
 - detection of, 267
 - treatment of, 206
- Vulvar irritants, 221
- Vulvar vestibulitis
 - bacterial infection and, 945
 - clinical features of, 945
 - colposcopy with, 221
 - definition of, 945
 - diagnosis of, 221
 - epidemiology of, 221, 945
 - etiology of, 221, 945
 - histology of, 221
 - histopathology of, 945
 - inflammatory mediators in, 945
 - and interstitial cystitis, 945
 - nociceptor pathways of, 945
 - pain in
 - anteriorly located, 945
 - mechanism of, 945
 - posteriorly located, 945
 - pathophysiology of, 945
 - pelvic floor muscles and, 945
 - primary, 221, 945
 - psychological considerations with, 221, 945
 - secondary, 221, 945
 - sexual dysfunction and, 945
 - treatment of
 - medical, 221, 945
 - studies of, evaluation of, 945
 - surgical, 221, 945
 - urinary oxalates and, 945
 - vestibular nerve sensitization in, 945
 - viral infection and, 945
- Vulvodynia
 - allergy-related, 221
 - with allodynia, 221
 - associated symptoms, 221
 - causes of, 221
 - classification of, 221
 - definition of, 221, 945
 - dysesthetic
 - clinical characteristics of, 221
 - etiology of, 221
 - treatment of, 221
 - erythema with, 221
 - with hyperesthesia, 221
 - local irritant-related, 221
 - onset of, 221
 - pathophysiology of, 221
 - prevalence of, 221
 - vaginal conditions mimicking, 221
 - vaginismus with, 221
- Vulvovaginal candidiasis, 184
- Vulvovaginitis
 - candidal, 221
 - causes of, uncommon or rare, 184
 - cyclic, 221
 - examination of patient with, 184
 - mycotic, 184
 - non-candidal, 221
 - recurrent, 221
- Warts, genital, 206. *See also* Human papillomavirus (HPV), infection
 - treatment of, 206
- Weaver's syndrome
 - antepartum surveillance for, 766

1038 INDEX

- pathophysiology of, 766
- Western blot test, for toxoplasmosis diagnosis, 81
- WIC, benefits of, 725
- Wiskott-Aldrich syndrome, 390
- Women and Infants Transmission Study, 121
- World Health Organization
 - nomenclature of sperm movement characteristics, 957
 - standards for normal semen analysis parameters, 957
 - standards for normal sperm morphology, 957
- Yeast, resistant, recurrent vulvovaginitis caused by, 184
- ZIFT. *See* Zygote intrafallopian transfer
- Zinc, dietary supplementation with, in preeclampsia, 436
- Zoladex. *See* Goserelin
- Zona pellucida antibodies, and infertility, 979
- Zygote intrafallopian transfer, 687

Author Index

- Adamson, G. David, 633
Barbieri, Robert L., 196
Barton, John R., 455
Belfort, Michael A., 479
Berkus, Michael D., 766
Boardman, Lori A., 945
Branch, D. Ware, 360
Brown, CAROLYN V., 306
Buller, Richard E., 863
Burns, William N., 586
Burrows, Robert, 327
Bussel, James B., 335
Buster, John E., 23
Carson, Sandra A., 2
Carson, Sandra Ann, 1
Clark, Ann L., 368
Cohen, Matthew A., 48
Connolly, Anna Marie, 820
Conway, Debra, 766
Crino, Jude P., 71
Davidson, Ezra, 725
Davis, Gordon D., 221
Dekker, Gustaaf A., 422
Dodson, Mark K., 916
Dokras, Anuja, 687
Dooley, Sharon L., 737
Dubinsky, Ted, 902
Egerman, Robert S., 381, 551
Eriksen, Nancy L., 121
Esplin, M. Sean, 360
Farmer, Richard M., 802
Fausett, Bardett, 390
Friedman, Steven A., 470
Giannina, Gregg, 479
Graczykowski, Jacek W., 9
Gregory, Kimberly D., 725
Grimes, David A., 972
Guzick, David S., 611, 883
Haefner, Hope K., 184
Helfgott, Andrew, 149
Herd, J. Allan, 479
Herschel, Marguerite, 163
Hoeger, Kathleen M., 611, 883
Honoré, Gerard M., 699
Hutchison, Christopher V., 221
Johnson, Jeffery R., 317
Katz, Vern L., 802
Kelton, John G., 327
Kim, Alexis H., 633
Langer, Oded, 766
Learman, Lee A., 849
Lense, Jorge, 39
Ling, Frank W., 664
Lubarsky, Suzanne L., 470
Mabie, William C., 519
Madden, Steven, 895
Magann, Everett F., 532
Mahavni, Vikas, 863
Martin, Dan C., 664
Martin, James N., Jr., 532
Mayer, James C., 39
Mittendorf, Robert, 163
Moghissi, Kamran S., 620
Mozurkewich, Ellen, 749
Natofsky, Jeryl G., 39
Newton, Edward R., 57, 59
Noller, Kenneth L., 183
Norwitz, Errol R., 436
Olive, David L., 687, 876
Paul, Maureen, 290
Paul, Richard H., 836
Peipert, Jeffrey F., 945
Pejovic, Tanja, 876
Pingeton, Diane M., 249
Piper, Jeanna M., 81
Pisarska, Margareta D., 2, 23
Pitkin, Roy M., 723
Porter, T. Flint, 895
Pryde, Peter, 163
Ramsay, Bruce, 939
Repke, John T., 436
Robinson, Julian N., 436
Rodgers, George M., 349
Rodis, John F., 107
Saleh, Ahmed, 31
Samuels, Philip, 317
Sauer, Mark V., 48
Sawaya, George F., 922
Schenken, Robert S., 565, 586
Schiff, Eyal, 470
Scott, James R., 862
Scott, L. Laurie, 134
Sedlacek, Thomas V., 206
Seifer, David B., 9
Sharp, Howard T., 916
Sheffield, Jeanne S., 97
Shehata, Nadine, 327
Shy, Kirk, 902
Sibai, Baha M., 381, 421, 455, 470, 551
Silver, Robert M., 316, 390
Skupski, Daniel W., 335
Sparks, Amy E.T., 957

1040 AUTHOR INDEX

Stirrat, Gordon M., 939
Stovall, Dale W., 979
Thorp, James A., 785
Thorp, John M., Jr., 820
Tulandi, Togas, 31
Valle, Rafael F., 276
Van Voorhis, Bradley J., 957, 979
Washington, A. Eugene, 922
Wen, Tony S., 81
Wendel, George D. Jr., 97

Williams, Michelle A., 163
Wing, Deborah A., 836
Winkel, Craig A., 645
Witlin, Andrea G., 455, 507
Witz, Craig A., 566
Yeko, Timothy R., 39
Young, Stephen B., 249
Zlatnik, Frank J., 757
Zweizig, Susan L., 267
Zylstra, Samuel, 234

